|
Erratum: Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study
Oct 22, 2026 Erratum: Modernizing Drug Development for Exceptional Therapies in High-Unmet Need Diseases: A Call for Pragmatism and Patient Centricity Oct 22, 2026 Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Oct 20, 2026 Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial Oct 19, 2026 Time-of-Day Immunotherapy: Why the Field Still Needs Randomized Evidence Oct 19, 2026 Effectiveness of a Multisite Oncology Financial Navigation Intervention: The Lessening the Impact of Financial Toxicity Clinical Trial Oct 16, 2026 Promise and Challenge of Personalized Lung Cancer Screening Oct 16, 2026 Beyond Phlebotomy: Iron Homeostasis in the Next Phase of Polycythemia Vera Management Oct 16, 2026 Expert Histopathologic Evaluation and Molecular Analyses for Ambiguous Cutaneous Melanocytic Tumors Oct 15, 2026 First-In-Human Study of 211At-CD45 Radioimmunotherapy With Nonmyeloablative Conditioning Hematopoietic Cell Transplantation for Adults With Hematologic Malignancies Oct 15, 2026 Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial Oct 14, 2026 Neurodevelopmental Blueprint in Gliomas: Toward an Ontogenetic Multimodal Integrated Therapy Oct 14, 2026 Selpercatinib in Pediatric and Adolescent Patients With RET-Altered Solid Tumors: Safety and Efficacy Results From the Phase I/II LIBRETTO-121 Study Oct 14, 2026 Clinical Trial Prediction Markets Oct 14, 2026 Radiation Oncology at a Crossroads: Interpreting the Evidence on Proton Versus Photon Radiotherapy for Oropharyngeal Cancer Oct 14, 2026 Prescription Does Not Ensure Patient Access: Progress and Remaining Challenges in Addressing Access Barriers to Specialty Oral Anticancer Medications Oct 14, 2026 Erratum: Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report From the Children's Oncology Group and the LEOPARD Study Oct 14, 2026 Erratum: Insurance and Cost-Related Access Barriers to Specialty Oral Anticancer Medications for Blood Cancers in a Nationwide Sample of Medicare and Commercially Insured Patients Oct 14, 2026 The Boy Who Became a Tiger Oct 13, 2026 VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy Oct 13, 2026 |
Purple Blossoms Journal of Clinical Oncology, Volume 44, Issue 30, Page 2972-2974, October 2026. <br/> 2026-10-20T07:00:00Z Bridging the Gap: Precision Oncology for Cancers of Unknown Primary Journal of Clinical Oncology, Volume 44, Issue 30, Page 2886-2890, October 2026. <br/> 2026-10-20T07:00:00Z Mindfulness and Tai Chi for Sleep, Fatigue, and Pain in Distressed People After Cancer Treatment: A Partially Randomized Patient-Preference Comparative Effectiveness Trial Journal of Clinical Oncology, Volume 44, Issue 30, Page 2929-2940, October 2026. <br/> 2026-10-20T07:00:00Z Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer Journal of Clinical Oncology, Volume 44, Issue 30, Page 2903-2907, October 2026. <br/> 2026-10-20T07:00:00Z Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial Journal of Clinical Oncology, Volume 44, Issue 30, Page 2941-2952, October 2026. <br/> 2026-10-20T07:00:00Z Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study Journal of Clinical Oncology, Volume 44, Issue 30, Page 2895-2902, October 2026. <br/> 2026-10-20T07:00:00Z Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update Journal of Clinical Oncology, Volume 44, Issue 30, Page 2953-2971, October 2026. <br/> 2026-10-20T07:00:00Z Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR Journal of Clinical Oncology, Volume 44, Issue 30, Page 2919-2928, October 2026. <br/> 2026-10-20T07:00:00Z Efficacy and Tolerability of Zenocutuzumab in Advanced NRG1 Fusion–Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial Journal of Clinical Oncology, Volume 44, Issue 30, Page 2908-2918, October 2026. <br/> 2026-10-20T07:00:00Z Should We Call Every Cancer a Rare Cancer? Journal of Clinical Oncology, Volume 44, Issue 30, Page 2891-2894, October 2026. <br/> 2026-10-20T07:00:00Z Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope? Journal of Clinical Oncology, Volume 44, Issue 30, Page 2976-2977, October 2026. <br/> 2026-10-20T07:00:00Z Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer? Journal of Clinical Oncology, Volume 44, Issue 30, Page 2975-2976, October 2026. <br/> 2026-10-20T07:00:00Z Erratum: Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression Journal of Clinical Oncology, Volume 44, Issue 30, Page 2979-2979, October 2026. <br/> 2026-10-20T07:00:00Z Erratum: Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation Journal of Clinical Oncology, Volume 44, Issue 30, Page 2979-2979, October 2026. <br/> 2026-10-20T07:00:00Z Erratum: Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study Journal of Clinical Oncology, Volume 44, Issue 30, Page 2980-2980, October 2026. <br/> 2026-10-20T07:00:00Z Reply to: “Is Dual-Checkpoint Blockade Beneficial Beyond Prolonging Chemoradiotherapy-to-Surgery Interval in Rectal Cancer?” and “Dual Immunotherapy in the Neoadjuvant Interval for Locally Advanced Rectal Cancer: A New Hope?” Journal of Clinical Oncology, Volume 44, Issue 30, Page 2977-2978, October 2026. <br/> 2026-10-20T07:00:00Z |
Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy
Among patients with relapsed small-cell lung cancer after chemotherapy, treatment with tambotatug pelitecan led to longer survival than treatment with topotecan, with fewer adverse events of grade 3 or higher. 2026-10-22
Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead The discovery of H. pylori has advanced the prevention and treatment of gastritis, peptic ulcers, and gastric cancer. Progress has been made in the research of H. pylori infection. These advances are discussed in this review. 2026-10-22
Reengineering Coagulation with a Bispecific Antibody Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa, who developed a prophylactic therapy for hemophilia A, have received the 2026 Lasker–DeBakey Clinical Medical Research Award. 2026-10-22
Case 30-2026: A 52-Year-Old Man with Vision Loss in the Left Eye A 52-year-old man with metastatic small-cell lung cancer was evaluated in the ophthalmology clinic because of vision loss in the left eye. A blood cytomegalovirus DNA viral load was 348 IU per milliliter. A diagnosis was made. 2026-10-22
In Vivo Aquaporin-1 Circular RNA Therapy for Radiation-Induced Xerostomia In a phase 1 study, RXRG001, a circular RNA encoding aquaporin-1, was administered to six patients with radiation-induced xerostomia. Measures of salivary flow improved, and adverse events were of grade 1 or 2 and transient. 2026-10-22
Ponatinib–Blinatumomab or Imatinib–Chemotherapy for Adult Ph-Positive ALL In a trial involving adults with Ph-positive acute lymphoblastic leukemia, 24-month event-free survival was 86% with the TKI–immunotherapy combination ponatinib–blinatumomab and 67% with imatinib plus chemotherapy. 2026-10-15
Lonvoguran Ziclumeran — In Vivo CRISPR Gene Editing in Hereditary Angioedema In a phase 3, randomized trial of lonvo-z, an in vivo gene-editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo. 2026-10-15
Case 29-2026: A 39-Year-Old Man with Abdominal Pain, Foot Drop, and a Spinal Mass A 39-year-old man, who was an Iraq War veteran with exposure to burn pits, was admitted to the hospital with hypertension, abdominal pain, and foot drop. Imaging showed a thoracic spinal mass. A diagnosis was made. 2026-10-15
Flushing in Carcinoid Syndrome A 44-year-old man was admitted for the management of carcinoid syndrome, which had been diagnosed 4 years earlier. On examination, mottled, violaceous, blanchable flushing was seen across the face and torso. 2026-10-15
Adapting to Genomic Medicine Hereditary angioedema is a disorder characterized by unpredictable, transient episodes of swelling and pain of various body parts. It can be life-threatening if the airway is involved. Current therapies include several different products that are administered prophylactically or at the onset of symptoms, and the prophylactic products must be administered... 2026-10-15
IARC Perspective on Lung Cancer Screening The 21st volume of the IARC Handbooks summarizes and evaluates evidence for the benefits and harms of lung cancer screening with low-dose CT or chest radiography and assesses tools and strategies to improve screening. 2026-10-15
Chemotherapy-free Treatment of Ph-Positive ALL It would be rare for anyone who has undergone intensive, multicycle, multiagent chemotherapy followed by allogeneic hematopoietic stem-cell transplantation to agree with Nietzsche’s personal view that “Out of life’s school of war, what does not kill me, makes me stronger.” Even though our past approaches to treating patients with the... 2026-10-15
Effect of Screening with Multicancer Early-Detection Test on Late-Stage Cancer Diagnosis In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. 2026-10-08
Advances in Systemic Treatment of Breast Cancer This review summarizes advances in therapy, including approval or expanded use of targeted agents, improved outcomes with antibody–drug conjugates and immunotherapy, and growing reliance on molecular profiling. 2026-10-08
Case 28-2026: A 19-Year-Old Woman with Fever, Cervical Lymphadenopathy, and Leukopenia A 19-year-old woman presented with fever and cervical lymphadenopathy. The white-cell count was 2900 per microliter (reference range, 4000 to 11,000), and the lactate dehydrogenase level was elevated. A diagnosis was made. 2026-10-08
A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer The diagnosis of cancer at earlier stages is generally associated with improved survival. Detecting circulating tumor–derived cell-free DNA (cfDNA) is an established method of monitoring the response to therapy for many cancer types, particularly hematopoietic and metastatic cancers — which leads to the question of whether screening for cfDNA in... 2026-10-08
Giredestrant plus Everolimus in Advanced Breast Cancer In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. 2026-10-01
Joint Clinical Assessments — A New Chapter in European Pharmaceutical Policy A new European Union regulation introduces a centralized clinical assessment process for comparing the effectiveness and safety of new medicines with those of the standards of care in various countries. 2026-10-01
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma In a phase 1 study of anito-cel, a CAR T-cell therapy, for relapsed or refractory myeloma, all 38 patients had a response. Severe cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome were rare. 2026-09-24
Etuvetidigene Autotemcel for the Treatment of Wiskott–Aldrich Syndrome Persons with Wiskott–Aldrich syndrome were treated with an autologous gene therapy consisting of hematopoietic stem and progenitor cells transduced ex vivo with a lentiviral vector encoding WAS complementary DNA. 2026-09-24
|
|
|
| |||
|
[Editorial] Microplastics and cancer: a looming threat?
Microplastics are a growing global concern and have been linked to various health conditions. A study presented by Ilias Dimeas and colleagues at the 2026 European Respiratory Society conference found a higher burden of microplastics in the lungs of patients with lung cancer than in those without cancer. In the study, 70% of 100 people undergoing a bronchoscopy had detectable microplastics in at least one sample, and patients with lung cancer were more likely to have detectable microplastics in their samples than patients without lung cancer. Thu, 01 Oct 2026 00:00:00 -0700
[Comment] Exercise oncology: from trials and guidelines to routine clinical care In oncology practice, there are trade-offs between quality of life and survival for many therapies. Similar trade-offs exist for drug reimbursement based on therapeutic effectiveness, affected population, and cost. Fri, 04 Sep 2026 22:30:01 +0000
[Comment] Looking at cancer burden in Africa through a new lens Cancer remains a leading cause of death and disability globally, with a disproportionate rising burden in Africa.1,2 Effective policy response has been consistently hampered by fragmented and incomplete cancer surveillance data.3 For a long time, there has been an assumption that a global uniform framework for understanding cancer risk factors exists and is applicable universally.4 This concept of harmonised global data is plausible in well structured and well resourced health systems in which research and care systems are integrated—systems that exist mostly in high-income regions. Thu, 01 Oct 2026 00:00:00 -0700
[Comment] Personalised medicine in oncology: inequality aversion in a fast-moving field Personalised medicine has been shown to improve patient care and holds promise to further benefit treatment results. The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research provides an overview of state-of-the-art treatments and the situation in low-income and middle-income countries (LMICs). From targeted treatment using companion diagnostics, identifying targets to guide treatment decisions, to broad ‘omics testing in cancer of unknown primary and metastasised tumours, the field is vast and inequalities exist within and between countries. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Ethical priorities in global cancer genomics and precision oncology Amid the promise of cancer genomics and precision oncology lies complex and ethically weighty issues. Genomics and other ‘omics are undoubtedly transforming cancer care for thousands of patients annually, enabling better prognosis, access to treatments or trials, or informing relatives. Yet, these interventions overwhelmingly benefit people in high-income countries: they are failing to reach most patients with cancer who could benefit, and those who are reached could, for reasons including health system readiness or data representation and interpretation, receive no or marginal benefit to their care. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Inequities in access to precision oncology: shared challenges, unified blueprint Precision oncology has substantially changed the therapeutic landscape from a “one size fits all” approach to that of individualised (or personalised) treatments.1 The promise of precision oncology extends across the entire cancer continuum from prevention, early diagnosis, subtyping of tumours, treatment selection, risk-adapted therapies, development of novel anticancer medicines, and post-treatment surveillance.2 The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research focuses on the current challenges and practical solutions to faciliate wider implementation. Fri, 25 Sep 2026 03:10:27 +0000
[Comment] Beyond the evidence: why multistakeholder cooperation will determine whether cancer genomics reaches patients The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology presents a worrying picture.1 While the number of precision oncology drugs continues to increase,2,3 access to testing and matched therapies remains profoundly unequal, research is concentrated in high-income countries (HICs) and populations of European ancestry, and expanding testing capacity has not always translated into proportionate population-level benefit. The Commission's survey of national cancer control programmes (NCCPs), conducted in collaboration with the Union for International Cancer Control and WHO International Agency for Research on Cancer (IARC) across 34 countries, found partial integration of genomics into most NCCPs, including in HICs. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Ecological neglect: critical oversight in precision oncology governance The Lancet Oncology Commission on accelerating equitable cancer genomics and precision oncology in health care and research1 examines the gap between the promise of precision oncology and its delivery across global health systems. Raffaella Casolino and colleagues argue that precision oncology has advanced with remarkable speed, yet its clinical impact and sustainability remain uneven, meaning that for much of the world, precision oncology remains just a promise. The authors argue that if the vision of precision oncology is to be realised, health systems need to generate, integrate, govern, and learn from data. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Affordability in the era of precision oncology Cancer drugs are increasingly unaffordable for health systems. Global spending on cancer drugs will reach US$441 billion by 2029.1 This 75% increase over 5 years cannot be explained by population ageing or changing prevalence alone. Instead, the price of cancer drugs is driving accelerated spending growth.2 Rising prices place considerable pressure on health systems, particularly when increased spending is not matched by commensurate improvements in patient health. Unfortunately, many expensive cancer drugs have highly uncertain safety and efficacy evidence at the time of market authorisation. Fri, 25 Sep 2026 03:10:03 +0000
[Comment] Counting who was not tested: artificial intelligence extraction of genomic and treatment data from hospital records The Lancet Oncology Commission on accelerating equitable access to cancer genomics and precision oncology provides an important framework defining indicators that health systems can and should measure.1 Operationalising these indicators, however, requires substantial data infrastructure. One indicator in the Commission's Precision Oncology Access Cascade defines the group of eligible patients who receive recommended genomic testing. The number of patients tested is relatively straightforward to obtain; however, the number meeting the guideline criteria is not because this information is usually recorded as unstructured narrative text rather than as a structured field. Fri, 25 Sep 2026 03:10:02 +0000
[Comment] Blank spaces on the map: genomics for global cancer research For most of the history of cancer genomics, the map of our knowledge has had blank spaces on it. In the Pan-Cancer Analysis of Whole Genomes, for example, roughly three quarters of donors were of European descent; samples from Latin American donors made up only about 1% of the large public repositories and samples from patients of Middle Eastern descent were almost entirely absent.1 Thu, 01 Oct 2026 00:00:00 -0700
[Comment] England's National Cancer Plan; ambition without accountability Publication of England's National Cancer Control Plan (NCCP) in February, 2026,1 marked a hard-won achievement, after years of advocacy from patients, clinicians, charities, parliamentarians, and The Lancet Oncology.2,3 The expectation was to address long-standing systemic issues in treatment delays and quality, workforce shortages, and inequalities; but hopes were quickly dashed.4 The plan had no real new money, no additional workforce capacity, no expansion of treatment infrastructure, no prioritisation, and no implementation strategy. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer We read with great interest the Article by Theodore L DeWeese and colleagues detailing the results of the PrTK03 phase 3 trial, which evaluated the addition of aglatimagene besadenovec (CAN-2409) and valacyclovir to standard-of-care external beam radiation therapy (EBRT) for localised prostate cancer.1 We commend the investigators for executing this decade-spanning study. The biological premise—using an adenoviral vector to exert localised cytotoxicity of a systemically administered prodrug while stimulating a T-cell-mediated immune response—is scientifically sound. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer – Authors' reply We thank Thomas Büttner and colleagues for their interest in our Article on the PrTK03 trial.1 In our trial, disease-free survival was the prospectively specified, US Food and Drug Administration-agreed primary endpoint under a Special Protocol Assessment, analysed in the intention-to-treat population and defined to include local failure, including positive biopsy, regional failure, distant metastasis, or death.1 The US Food and Drug Administration did not agree to use biochemical failure as a disease-free survival event. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues’ post-hoc analysis of the PACIFIC trial in The Lancet Oncology addresses an important and clinically timely question: whether baseline exposure to proton pump inhibitors or antibiotics modifies the benefit of durvalumab after concurrent chemoradiotherapy in patients with unresectable stage III non-small-cell lung cancer.1 The observed association between proton pump inhibitor exposure and inferior progression-free and overall survival in the durvalumab group, but not in the placebo group, is thought provoking. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC I read with great interest the Article by Leonardo Brunetti and colleagues,1 which reported that baseline exposure to proton pump inhibitors was associated with substantially inferior progression-free and overall survival among patients receiving durvalumab after concurrent chemoradiotherapy in the PACIFIC trial, but not among those receiving placebo. The use of a randomised, placebo-controlled dataset to separate prognostic from predictive associations is a genuine advance over observational literature. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues report an important post-hoc analysis of the PACIFIC trial,1 showing that baseline exposure to proton pump inhibitors, and to a lesser extent antibiotics, was associated with inferior survival outcomes following durvalumab, but not placebo, in patients with unresectable stage III non-small-cell lung cancer (NSCLC). The randomised placebo-controlled setting and differential analysis across the treatment group are major strengths. Nevertheless, proton pump inhibitor exposure itself was not randomised, and the clinical context in which proton pump inhibitors were prescribed could be crucial to interpretation. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC Leonardo Brunetti and colleagues report an association between proton pump inhibitor exposure and shorter overall survival among patients receiving consolidation durvalumab, but not placebo, in the PACIFIC trial, and propose gut dysbiosis as a potential underlying mechanism.1 We seek clarification on one aspect of the analysis and propose an alternative explanation. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC – Authors' reply We thank our colleagues for their thoughtful comments on our post-hoc analysis of PACIFIC.1 Their correspondence raises two issues: the definition of survival events and whether proton pump inhibitor exposure is causal or reflects its prescribing context. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 181–90 Tang C, Sherry AD, Hwang H, et al. Lancet Oncol 2026; 27: 181–90—In this Article, in the Baseline castration sensitivity row of table 2, the data for patients who are castration resistant and those who are castration sensitive were reversed. This correction has been made to the online version as of Sept 3, 2026. Thu, 03 Sep 2026 22:30:00 +0000
[Corrections] Correction to Lancet Oncol 2026; 27: 1043–56 Brunetti L, Santo V, Pinato DJ, et al. Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial. Lancet Oncol 2026; 27: 1043–56—The appendix of this Article has been corrected as of Sept 28, 2026. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 1077–93 Kudo M, Abou-Alfa GK, Ren Z, et al. Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. Lancet Oncol 2026; 27: 1077–93—In this Article, sentence eight of the Findings in the Summary should have read ‘post-embolisation syndrome’. In the Outcomes section of the Methods, the disease control rate at 20 weeks explanation has been corrected. Thu, 01 Oct 2026 00:00:00 -0700
[Corrections] Correction to Lancet Oncol 2026; 27: 1094–109 Le X, Passaro A, Zhao Y, et al. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2026; 27: 1094–109—In this Article, the second and third sentences of the ninth paragraph of the Results section should have read “The most common immune-related treatment-related adverse events of any grade in the ivonescimab plus chemotherapy group were hypothyroidism (18 [8%]) and hyperthyroidism (nine [4%]), and in the placebo plus chemotherapy group were rash (seven [3%]), alanine aminotransferase increased (seven [3%]), aspartate aminotransferase increased (six [3%]), and amylase increased (six [3%]). Thu, 01 Oct 2026 00:00:00 -0700
[News] Trump cuts childhood vaccine recommendations The US President Donald Trump has issued an executive order stressing “maximal parental choice” and cutting the number of childhood vaccines recommended by the federal government to 11 from 18. Thu, 20 Aug 2026 22:30:04 +0000
[News] Nigeria plans major expansion of radiotherapy capacity Africa's most populous country Nigeria plans to procure and install 35 additional linear accelerators (LINACs), substantially expanding its radiotherapy capacity. Six Cancer Centres of Excellence are also being developed, with centres in Katsina, Enugu, and Benin completed and commissioned. However, the new machines translating into wider access depends on availability of specialist staffing, maintenance, financing, and where the additional capacity is located. Thu, 20 Aug 2026 22:30:01 +0000
[News] Delays in cancer referrals and care lead to harm and missed diagnoses in England Late and missed diagnoses, delays in cancer care, and physical harm were partly caused by England's National Health Service (NHS) system for general practitioners (GPs) seeking specialist advice before patient referral to hospital, according to an investigation by the Health Services Safety Investigations Body (HSSIB). Thu, 27 Aug 2026 22:30:01 +0000
[News] Increased tobacco production and cigarette imports in Africa While tobacco-leaf production across the world declined by 19% between 2012 and 2024, it increased by 9% in Africa, according to a WHO analysis published on Aug 31, 2026. Moreover, during this period, there was a more than two-times increase in cigarette imports to Africa—from US$833 million to $1·77 billion. Thu, 10 Sep 2026 22:30:01 +0000
[News] 2026 World Conference on Lung Cancer Interim results from the phase 3 ARTEMIS-008 trial, presented by Jie Wang (Chinese Academy of Medical Sciences, Beijing, China), suggest risvutatug rezetecan, a B7-H3-directed antibody–drug conjugate (ADC), could be the new standard of care in relapsed small-cell lung cancer (SCLC). Patients were randomly assigned (1:1) to receive risvutatug rezetecan (8·0 mg/kg; n=230) or topotecan (1·2 mg/m2 on days 1–5; n=231) every 3 weeks. At a median follow-up of 12·2 months, overall survival (the primary endpoint) was significantly improved with risvutatug rezetecan compared with topotecan (18·5 vs 10·3 months; HR 0·46 [95% CI 0·35–0·62). Thu, 17 Sep 2026 22:30:02 +0000
[News] Kenya agrees major cuts to cancer drug prices The Kenyan Government has agreed a deal with Pfizer that could reduce the price of selected cancer medicines by seven times. Costs are expected to drop from as much as 1 million Kenyan Shillings (KSh; US$7725) to below KSh50 000 ($386) per treatment cycle for some drugs. The agreement covers nine cancers: breast, stomach, colorectal, lung, prostate, and oesophageal cancers, as well as leukaemia, lymphoma, and multiple myeloma. Thu, 17 Sep 2026 22:30:01 +0000
[News] Toxic dust around the World Trade Center On Sept 8, 2026, New York City authorities released more than 170 000 pages of documents showing that officials misled the public about toxic air quality levels after the Sept 11, 2001, attack that killed more than 2600 people at the World Trade Center (WTC). Health researchers say the documents contain little medical information that is new but confirm that carcinogens and toxins were present months after the attacks, exposing 400 000 people in lower Manhattan to smoke, dust, and combustion products. Thu, 17 Sep 2026 22:30:02 +0000
[Perspectives] Cancer's new anxiety: not a death sentence, but delay Throughout the history of cancer research, hyperbole has never been in short supply—whether it be Richard Nixon's war, Joe Biden's moonshot, or Cancer Research UK's 2023 declaration of a golden era. Driving such rhetoric has been the need to act against an enduring societal concern—cancer, the so-called Big C, society's number one fear. Thu, 01 Oct 2026 00:00:00 -0700
[Perspectives] Against cancer, not against dying: Ernest Becker in the oncology clinic When American cultural anthropologist Ernest Becker was awarded the 1974 Pulitzer Prize for his book, The Denial of Death, he had died of colorectal cancer only 2 months earlier. More than half a century later, the book feels almost uncomfortably contemporary in the oncology clinic. Although the book does not address cancer care directly, it speaks to what cancer reveals: mortality, and the symbolic structures we build to make that knowledge bearable. For Becker, identities, professions, institutions, religions, families, reputations, and achievements are ways in which the fragile self seeks continuity beyond finitude. Thu, 01 Oct 2026 00:00:00 -0700
[Perspectives] Sir Chris Hoy's Tour de 4 charity cycle ride returns Mention the name Chris Hoy and it's natural to picture the Olympic cyclist, who won six gold medals and one silver in Sydney, Athens, Beijing, and London between 2000 and 2012. Fans voted for him to be named as the BBC Sports Personality of the Year in 2008, and he was knighted by the late Queen Elizabeth in the 2009 New Year honours list. However, over the past 2 years, Hoy has become famous for a completely different reason. In October, 2024, he revealed that he had received a terminal diagnosis of stage-4 prostate cancer, which had spread to his bones. Sun, 06 Sep 2026 23:01:02 +0000
[Perspectives] Differing approaches to cancer at the Edinburgh Fringe “I had cancer a couple of years ago—I don’t like to talk about it,” grinned comedian Matt Forde during his show at the Edinburgh Festival Fringe, the world's largest arts festival, which took place in Edinburgh, UK, on Aug 7–31, 2026. With a sly grin at his audience, he added “I’m not going to use it to sell tickets for another sold out night in Edinburgh.” Forde, who is best known for his impressions of politicians, was diagnosed in July, 2023, with a chordoma, a very rare sarcoma at the base of his spine. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial Pembrolizumab plus chemotherapy followed by maintenance with pembrolizumab–olaparib showed a statistically significant and clinically meaningful improvement in progression-free survival versus chemotherapy, suggesting that this regimen might have potential for patients with newly diagnosed BRCA non-mutated stage III–IV epithelial ovarian cancer. Mon, 07 Sep 2026 22:30:04 +0000
[Articles] Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis Our findings highlight the importance of infection control to achieve cancer prevention. Scientifically proven, but often underused, approaches include HPV and HBV vaccination; testing and treatment of HIV, H pylori, HBV, and HCV; safe injection practices; access to condoms and pre-exposure prophylaxis to prevent HIV transmission; and screening of precancerous lesions for HPV-driven cervical and anal cancer. Our findings also inform the investment cases for research and development for new prevention tools, most notably for EBV. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer (CHN HYPOPMRT): 10-year outcomes from a randomised, non-inferiority, open-label, phase 3 trial Hypofractionated postmastectomy radiotherapy provided durable locoregional control with no increase in severe late adverse events compared with conventional fractionation, supporting its use as a more time-efficient option than conventional fractionated radiotherapy. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Patient-reported symptom monitoring in patients with lung cancer (SYMPRO-Lung trial): long-term, post-hoc survival results of a multicentre, stepped-wedged, cluster-randomised clinical trial Weekly PRO symptom monitoring was associated with meaningful improvement in long-term overall survival among patients with stage I–IV lung cancer. Median overall survival was 5 months longer in the intervention group than in the control group. These findings underscore the value of implementing PRO symptom monitoring within routine care for patients with lung cancer. Fri, 11 Sep 2026 22:30:01 +0000
[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial OPTIMUM shows sustained progression-free survival and overall survival improvement with risk-stratified extended therapy, supporting implementation of molecular diagnostics and tailored treatment in patients with newly diagnosed high-risk multiple myeloma. Mon, 07 Sep 2026 22:30:01 +0000
[Articles] An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial The STAMINA lifestyle intervention meets best practice guidelines, can be implemented in NHS trusts in England, and offers clinicians a clear basis for identification and prescription of a supervised exercise and dietary advice intervention to mitigate negative effects associated with ADT. Fri, 04 Sep 2026 22:30:01 +0000
[Articles] Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era The CPI2 model, using 14 readily available clinical parameters, demonstrated improvement in discriminative accuracy compared with the IMDC model. This classification should be further validated in other trial and observational populations and be used to reanalyse heterogeneity of treatment effects of immune checkpoint inhibitor-based combination regimens in trials shaping the current and future treatment landscape. Wed, 09 Sep 2026 22:30:01 +0000
[Articles] Long-term exposure to wildfire-related PM2·5 and overall survival of older patients with lung cancer: a retrospective, registry-based cohort study Wildfire-related PM2·5 showed greater toxicity per unit exposure than non-wildfire PM2·5. As wildfire-related PM2·5 is the fastest-growing contributor to ambient air pollution, there is an urgent need for updated strategies to manage wildfires and mitigate their effects. Tue, 15 Sep 2026 22:30:01 +0000
[Articles] Burden of cancer in Africa, 1990–2023: a systematic analysis from the Global Burden of Disease Study 2023 Cancer is a growing contributor to the disease burden in Africa, with rising cases, deaths, and DALYs disproportionately affecting children, adolescents, and young adults. The increase in age-standardised mortality and DALY rates stands in sharp contrast to the ambitions of the Sustainable Development Goals for 2030 and the African Union Agenda 2063. Addressing this burden will require coordinated national and international action, with health-system strengthening and context-specific cancer-control strategies spanning prevention, early diagnosis, and treatment. Tue, 15 Sep 2026 22:30:01 +0000
[The Lancet Oncology Commission] Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission Cancer genomics and precision oncology are increasingly central to cancer care, but many health systems struggle to implement them equitably, effectively, and sustainably. This Commission defines the current global precision oncology landscape and analyses the scientific, structural, and health-system challenges shaping its delivery and impact. Findings indicate that access to cancer genomics and precision oncology remains profoundly unequal across and within countries, leaving millions of patients without guideline-indicated interventions each year. Fri, 25 Sep 2026 03:10:28 +0000
[Policy Review] Balancing benefits, costs, and harms: policy implications of expanding cancer susceptibility testing from genetics clinics to the general population Cancer susceptibility testing is rapidly advancing beyond specialist genetics clinics into routine oncology and population-level genomics initiatives. This expansion positions germline pathogenic variants in cancer susceptibility genes and polygenic risk scores as crucial tools for precision prevention, surveillance, and early detection. However, implementation has outpaced the evidence needed to justify testing at scale, particularly in well populations. For a small number of first-wave genes—including BRCA1, BRCA2, MLH1, and MSH2—cancer risks are well established and downstream medical interventions are supported by substantial observational evidence, albeit with an absence of randomised trials. Fri, 25 Sep 2026 03:10:02 +0000
[Review] Cancer and the microbiome: from association to intervention The gut microbiome is increasingly recognised as a clinically modifiable determinant of efficacy and toxicity across systemic cancer therapies, with the most mature evidence in patients receiving immune checkpoint inhibitors (ICIs). The composition and function of intestinal microbes can influence treatment outcomes by affecting immune priming, antigen presentation, host–microbial co-metabolism, drug biotransformation, and epithelial barrier integrity. In melanoma, non-small-cell lung cancer, and renal cell carcinoma, higher microbial diversity, ecological stability, and enrichment of immunostimulatory pathways have been associated with improved ICI response and survival. Thu, 01 Oct 2026 00:00:00 -0700
[Clinical Picture] Not all thoracic micronodules are metastases A 58-year-old female, lifelong non-smoker with history of Parkinson's disease, presented with a palpable right breast lump to the Odette Cancer Centre at Sunnybrook Health and Sciences Centre (Toronto, ON, Canada) in April, 2024, and was diagnosed with right-sided oestrogen receptor-positive, HER2-positive breast cancer (cT3N0). She received neoadjuvant dose dense doxorubicin–cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab. Lumpectomy and sentinel lymph node biopsy was performed revealing a pathological complete response. Thu, 01 Oct 2026 00:00:00 -0700
|
Risk factors and outcome of children and young adults with initially unresected nonrhabdomyosarcoma soft tissue sarcoma: An analysis from the International Soft Tissue Sarcoma Consortium
Outcomes were more favorable with the combination of chemotherapy and RT (pre‐ or postoperative) versus no RT for initially unresected NRSTS. Patients with large synovial sarcoma may benefit from contemporary trial designs incorporating more of a risk‐based directed neoadjuvant chemotherapy and RT approach. Higher R0 margin status rates were achieved in protocols with specified preoperative RT, which resulted in improved outcomes. Thu, 22 Oct 2026 06:50:16 -0700 Issue Information Thu, 22 Oct 2026 06:43:28 -0700 |
Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer: A Randomized Clinical Trial
This randomized clinical trial examines the relationship between digital patient-reported outcome monitoring with alert-based responses and fatigue in patients with metastatic breast cancer. Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer This retrospective modeling and validation study uses clinical trial data to develop mathematical biomarkers that predict outcomes of patients with prostate cancer undergoing adaptive therapy. Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer This cohort study examines the occurrence and rate of metabolic syndrome during the first year following initiation of androgen deprivation therapy–androgen receptor pathway inhibitor. Trends in Meningioma Incidence, Treatment, and Imaging Surveillance This quality improvement study examines incidence, treatment, and surveillance patterns in meningioma care in Denmark from 2010 to 2023 to identify potentially unnecessary follow-up imaging. Federal and Industry Sponsorship in US Cancer Clinical Trials This comparative study of cancer clinical trial portfolios assesses differences between federal and industry sponsors in cancer clinical trial research. Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients This cohort study assesses market dynamics and examines financial implications associated with biosimilar use patterns among patients who received bevacizumab, rituximab, or trastuzumab. Racial and Ethnic Disparities in US Colorectal Cancer Mortality by County, Sex, and Age This cross-sectional study assesses variation in colorectal cancer mortality rates and changes over time across county, race and ethnicity, sex, and age in the US. Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review This narrative review discusses chemotherapy decision-making support tools and updated evidence guiding therapeutic decision-making among older adults with early-stage breast cancer. Oral Ulcers in a Patient With Myelodysplastic Syndrome A 79-year-old woman with high-risk myelodysplastic syndrome treated with 5-azacitidine presented with painful ulcers on the tongue and right lower extremity. What is your diagnosis? Redefining Progression in a Rapidly Evolving Therapeutic Landscape This Viewpoint the regulatory problem of how to design clean trials that regulators seek as the field of oncology becomes more therapeutically sophisticated. Recent Food and Drug Administration Decisions and the Future of the Development of Cancer Drugs in the US This Viewpoint discusses recent US Food and Drug Administration (FDA) decisions regarding oncology drug trials for refractory melanoma and their potential negative impacts on the US regulatory environment. Academy of QI—Learning Leadership by Quality Improvement This Viewpoint discusses the strong connection between quality improvement and leadership development. Managing Metabolic Syndrome and Prostate Cancer Supplements and Wellness Products During Cancer Care This Hindsight Bias in Diagnosis This essay discusses the public discourse around “missed” diagnoses and how physicians should engage patients early in diagnostic reasoning. Overlapping Cohorts and Double Counting in Meta-Analyses Overlapping Cohorts and Double Counting in Meta-Analyses—Reply Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability Concerns Regarding NSCLC Immunoradiotherapy Study Interpretability—Reply Adult T-Cell Leukemia/Lymphoma and Maternal Screening Adult T-Cell Leukemia/Lymphoma and Maternal Screening—Reply JAMA Oncology |
|
|
| |||
|
[Editorial] Personalising AML treatment: beyond age and fitness
Over the past couple of decades, the number of treatment options for patients with acute myeloid leukaemia has accelerated; however, most patients still do not survive long-term, with 5-year overall survival around 30%. For younger and functionally fit patients, the predominant front-line therapy has remained unchanged for half a century: intensive induction chemotherapy that includes cytarabine and anthracyclines (the 7+3 regimen). For older patients or those not able to undergo intensive chemotherapy, a combination of hypomethylating agent and venetoclax is now the standard front-line therapy, spearheaded by the VIALE-A trial in 2020. Thu, 01 Oct 2026 00:00:00 -0700
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia Nicolò Peccatori and colleagues provide evidence for inotuzumab ozogamicin in paediatric very-high-risk first-relapse B-cell acute lymphoblastic leukaemia.1 The data support a less toxic bridge to haematopoietic stem cell transplantation (HSCT), but the response denominators support a more specific clinical interpretation: inotuzumab ozogamicin is best viewed as cycle-1 molecular triage, not prolonged reinduction or a replacement for UK ALLR3 chemotherapy. Because ITCC-059 was a single-arm study and its statistical design was modified from 43 to 31 patients while increasing the alpha-error to 10%, comparative claims should be reframed as response-adapted sequencing. Wed, 09 Sep 2026 22:30:04 +0000
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply We appreciate discussing the ITCC-059 results in response to Xiaogang Hao and colleagues. Wed, 09 Sep 2026 22:30:01 +0000
[In Focus] From approval to practice: are clinicians and health systems ready for gene therapy in sickle cell disease? Once a scientist's dream, gene therapy for sickle cell disease has now entered clinical practice. Autologous gene-based therapies offer a potential curative option for a disease that affects approximately 7·7 million people worldwide and remains associated with substantial morbidity, premature mortality, and entrenched health inequities. Regulatory approval, however, represents only the first step in a much longer translational pathway. Experience from other high-cost innovations suggests that without concurrent investment in implementation, workforce preparation, and financing, access could remain uneven or delayed. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Vernon Louw: expanding access to clinical haematology in Africa Vernon Louw was not that interested in haematology at first. As an undergraduate he had found the teaching “very laboratory based” and he “struggled to connect it with the patients behind the results”. This sentiment changed when he began treating patients with haematological malignancies as a registrar in internal medicine. “I came to appreciate that haematology combines complex diagnostic reasoning, laboratory science, and long-term relationships with patients in a particularly compelling way”, he recalled. Thu, 01 Oct 2026 00:00:00 -0700
[In Focus] Integrating sexual health into sickle cell disease care Sexual health is a fundamental component of overall wellbeing, yet it remains one of the least addressed dimensions of care for people living with sickle cell disease. At the ASCAT 2025 meeting in London, UK, ERN-EuroBloodNet and RADeep registry convened a 3-day patient educational workshop dedicated to this topic. The sessions brought together 27 people living with sickle cell disease and a multidisciplinary team comprising one obstetrician, one internist, two haematologists, and two psychologists, creating an intergenerational and intercultural space, with 13 countries represented to exchange perspectives. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2) To our knowledge, this is first clinical study of a Bruton tyrosine kinase inhibitor, rilzabrutinib, in warm autoimmune haemolytic anaemia. Rilzabrutinib showed robust overall and durable haemoglobin response and favourable safety in patients with previously treated warm autoimmune haemolytic anaemia. Rilzabrutinib has the potential to treat the underlying pathophysiology of warm autoimmune haemolytic anaemia through multi-immune modulation, induce a robust and sustained haemoglobin response, and provides an opportunity to decrease or stop corticosteroid use. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial Rilzabrutinib showed continued, stable, and sometimes improved platelet responses, including in patients who were initially non-responsive in the double-blind trial. Additionally, rilzabrutinib improved several disease aspects, including physical fatigue and bleeding, supporting its multi-immune modulation mechanism in immune thrombocytopenia, and had a favourable safety profile. The long-term extension period of LUNA3 will further characterise the long-term efficacy and safety of rilzabrutinib in patients with difficult-to-treat immune thrombocytopenia, and the ongoing LUNA4 trial (NCT07007962) will determine the efficacy of rilzabrutinib in earlier-line treatment and its potential to achieve sustained treatment-free response. Thu, 17 Sep 2026 22:30:01 +0000
[Articles] Felzartamab plus lenalidomide–dexamethasone versus lenalidomide–dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial Felzartamab plus lenalidomide–dexamethasone significantly prolonged progression-free survival compared with lenalidomide–dexamethasone alone, supporting felzartamab plus lenalidomide–dexamethasone as a potential new treatment option for Chinese patients with relapsed or refractory multiple myeloma. Thu, 01 Oct 2026 00:00:00 -0700
[Articles] Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial Topical ruxolitinib showed significant clinical activity and favourable harms profile in active cutaneous cGVHD. Ruxolitinib cream could represent a steroid-sparing, skin-directed alternative or second-line therapy, expanding treatment options for patients with cutaneous cGVHD. Wed, 16 Sep 2026 22:30:02 +0000
[Review] High time for risk-adapted treatment in mantle cell lymphoma Mantle cell lymphoma has multiple treatment options, yet the disease is difficult to cure. Relapses are common, treatments can cause severe side-effects, and current recommendations are still largely based on age rather than biology. Although suitability for intensive treatment was previously the decisive parameter, increasing knowledge on the biology of mantle cell lymphoma and less toxic targeted therapies has made non-risk adapted treatments outdated. TP53 mutations or deletions, blastoid histology, and a high Ki-67 proliferation index consistently identify patients at high risk of relapse. Wed, 02 Sep 2026 22:30:01 +0000
[Review] At the heart of unmet need: TP53 myeloid neoplasms TP53 myeloid neoplasms are being increasingly encountered in clinical practice and have been recognised in 2022, as a unique entity in the setting of functional loss of the two copies of the gene. The classification of myeloid neoplasm based on presence of biallelic (multi-hit) TP53 should precede morphological classification. The identification of biallelic (multi-hit) inactivation continues to evolve and is a matter of great debate balancing definitive biallelic identification via assays, pathology classifications, and clinical applicability. Thu, 01 Oct 2026 00:00:00 -0700
[Personal View] Redefining plasma cell leukaemia Plasma cell leukaemia is an aggressive plasma cell malignancy characterised by the presence of a high percentage of circulating clonal plasma cells on conventional peripheral blood smear examination. We argue that plasma cell leukaemia must no longer be considered as a separate disease entity but as a type of high-risk multiple myeloma. With the adoption of more strict criteria for defining high-risk multiple myeloma and the relaxation of criteria in defining plasma cell leukaemia, the clinical implications of the terms have converged. Fri, 21 Aug 2026 22:30:01 +0000
|
No cure without consequence: HCT and CH in SCD
Volume 148, Issue 17 October 22 2026 One CAR is good; are 2 CARs better? Volume 148, Issue 17 October 22 2026 Addressing CAR T-cell exhaustion through gene silencing Volume 148, Issue 17 October 22 2026 LIN28B: LINeage-dependent oncogene or tumor suppressor? Volume 148, Issue 17 October 22 2026 DEK: once a translocation partner, now an oncogenic effector Volume 148, Issue 17 October 22 2026 Age-related anemia: a new microbial clue in old blood Volume 148, Issue 17 October 22 2026 Reframing APS thrombogenesis: a new PF4-driven mechanism Volume 148, Issue 17 October 22 2026 Characteristics of donor and recipient clonal hematopoiesis in nonmyeloablative transplant for sickle cell disease Hematopoietic cell transplantation (HCT) offers a potentially curative therapy for sickle cell disease (SCD), but posttransplant complications, including clonal hematopoiesis (CH), may limit its long-term benefits. In a Plenary Paper, Weeks and colleagues identify newly emergent, donor-derived, and persistent recipient CH in a minority of patients after HCT, with TP53 mutations particularly associated with subsequent transplant-related myeloid neoplasms. These findings provide new insight into clonal evolution after HCT and the risks associated with HCT for SCD.
Volume 148, Issue 17 October 22 2026 How I treat autoimmune neutropenia in adults Autoimmune neutropenia (AiN) in adults is a rare, often chronic disorder with variable severity and poorly understood mechanisms of neutrophil destruction. In this How I Treat article, Leaf and Sykes explore the pathophysiology, diagnosis, and treatment of the disease through 4 illustrative cases. They underscore the need for an individualized approach and advocate for further research to better define disease mechanisms and develop more effective treatments.
Volume 148, Issue 17 October 22 2026 Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma Antigen loss is a major mechanism of relapse after B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma, prompting various strategies to target multiple antigens. One is to administer 2 distinct products together. Mailankody and colleagues report the results of the Targeting Antigens with Novel Dual Effector cells for Multiple Myeloma (TANDEMM) phase 1 study, showing that concurrent administration of BCMA- and GPRC5D-directed CAR T cells is safe and can be effective in a heavily pretreated population. However, relapse in some patients through antigen loss and unequal CAR T-cell expansion indicates that dual targeting does not fully prevent resistance.
Volume 148, Issue 17 October 22 2026 Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial Chimeric antigen receptor (CAR) T-cell exhaustion limits the durability of responses in lymphoma, highlighting the need to preserve T-cell function during therapy. Kim et al attempted to achieve this by knocking down expression of 2 inhibitory receptors in a new CD19-directed CAR T-cell product. They report a 67% complete response rate in relapsed/refractory large B-cell lymphoma (LBCL) in a phase 1/2 trial of anbalcabtagene autoleucel, which uses gene silencing technology to reduce programmed death 1 (PD-1) and TIGIT expression. However, progression remains common, underscoring the need to determine whether targeting additional exhaustion pathways can improve long-term disease control.
Volume 148, Issue 17 October 22 2026 LIN28B is essential for human fetal B-lymphopoiesis and initiation of KMT2A::AFF1 infant leukemia Infant B-cell acute lymphoblastic leukemia (B-ALL) is driven by developmental programs that enable leukemic transformation of fetal hematopoietic cells. Ling and colleagues show that the fetal development–specific RNA-binding protein LIN28B is required for the initiation and maintenance of KMT2A::AFF1-positive infant B-ALL by promoting proliferation, B-cell differentiation, and cell survival. These findings identify LIN28B as a potential therapeutic target while highlighting its context- and lineage-dependent role in infant leukemia.
Volume 148, Issue 17 October 22 2026 Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming Casein kinase 2 (CK2) signaling contributes to acute myeloid leukemia (AML) stem cell maintenance, but the mechanisms linking this pathway to leukemic transformation remain undefined. Lei and colleagues show that CK2-dependent phosphorylation of DEK, an abundant nonhistone chromatin protein, promotes recruitment of the transcription factor GABPA to drive PBX3 expression, sustaining AML stemness, and demonstrate that pharmacological CK2 inhibition with CX-4945 synergizes with venetoclax to delay disease progression. These findings identify a CK2-DEK-GABPA-PBX3 pathway as a potential therapeutic vulnerability in AML.
Volume 148, Issue 17 October 22 2026 The gut microbiota drives aging-related erythropoiesis impairment via phenylacetic acid–induced histone phenylacetylation Anemia of aging is common, but its underlying mechanisms often remain unexplained despite standard diagnostic evaluation. Xie and colleagues identified an Odoribacter splanchnicus–phenylacetic acid pathway that impairs erythroid differentiation through histone phenylacetylation through disruption of the GATA switch required for normal erythroid maturation. These findings link aging-associated gut dysbiosis to impaired erythropoiesis and suggest potential microbiome- or metabolite-directed therapeutic strategies.
Volume 148, Issue 17 October 22 2026 Antiphospholipid syndrome is a platelet factor 4–centric immunothrombotic disorder Antiphospholipid syndrome (APS) is a thromboinflammatory disorder in which the mechanisms that drive severe thrombosis remain incompletely understood. Field and colleagues show that platelet factor 4 (PF4), a chemokine released from platelets, forms a large trimolecular complex with β2 glycoprotein I (β2GPI) and neutrophil extracellular traps that enhances anti-β2GPI antibody recognition and promotes platelet and neutrophil activation and thrombosis. These findings expand the traditional β2GPI-centered model of APS and identify PF4 as a potential therapeutic target.
Volume 148, Issue 17 October 22 2026 Kauskot A, Vandenbriele C, Louwette S, et al. PEAR1 attenuates megakaryopoiesis via control of the PI3K/PTEN pathway. Blood. 2013;121(26):5208-5217. Volume 148, Issue 17 October 22 2026 Chen L, Hu L, Liu X, et al. Single-cell profiling of ANKRD26 thrombocytopenia reveals progenitor expansion and polyploid apoptosis via JUNB-p21. Blood. 2026;147(17):1984-1998. Volume 148, Issue 17 October 22 2026 |
Heritability of Transcranial Doppler Velocity in Sickle Cell Anemia Across Two Independent Pediatric Cohorts
Thu, 22 Oct 2026 19:39:34 -0700 Longevity in Thalassemia: Which Clock Are We Trying to Slow? Wed, 21 Oct 2026 18:30:30 -0700 Outcomes of Patients With AL Amyloidosis and End‐Stage Renal Disease After Initiation of Therapy Wed, 21 Oct 2026 07:34:46 -0700 Voxelotor in Children With Conditional Cerebral Blood Flow Velocity: What HOPE Kids 2 Teaches Us About Efficacy, Mortality, and Malaria Risk in Africa Tue, 20 Oct 2026 21:05:19 -0700 Utilization and Outcomes of Hemodialysis and Peritoneal Dialysis in Sickle Cell–Attributed End‐Stage Kidney Disease Mon, 19 Oct 2026 10:10:45 -0700 Rusfertide for Polycythemia Vera: Incremental Benefit Assessment Sat, 17 Oct 2026 04:58:57 -0700 A Novel Molecular Etiology of Paradoxical Hereditary Thrombocytosis Caused by Germline JAK2 Loss‐of‐Function Sat, 17 Oct 2026 03:38:20 -0700 Clarifying Transfusion Endpoint and Safety Reporting in the Phase III rhTPO Trial Fri, 16 Oct 2026 21:39:25 -0700 A Myeloma Masquerade: CCND3‐Rearranged Plasma Cell Myeloma Mimicking Lymphoplasmacytic Lymphoma Wed, 14 Oct 2026 21:15:06 -0700 Combination Therapy of Vinblastine, Prednisolone, Methotrexate, and 6‐Mercaptopurine as a Front‐Line Therapy for Adult Patients With Langerhans Cell Histiocytosis Wed, 14 Oct 2026 21:13:45 -0700 Plasma Exchange and Daratumumab for Myeloma Cast Nephropathy Mon, 12 Oct 2026 21:04:54 -0700 Issue Information Mon, 12 Oct 2026 05:55:51 -0700 Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia Mon, 12 Oct 2026 05:55:51 -0700 Primary Plasma Cell Leukemia Mon, 12 Oct 2026 05:55:51 -0700 Myeloma Progression Without Osteolysis: Rethinking Whole‐Body Low‐Dose CT Criteria for Bone Disease Mon, 12 Oct 2026 05:55:51 -0700 Robustness of Hemophagocytic Lymphohistiocytosis Risk Estimates in CAR T‐Cell Therapy Mon, 12 Oct 2026 05:55:51 -0700 Hypomethylating Therapy in VEXAS Syndrome: Disease Modification Beyond Bridging to Transplant Mon, 12 Oct 2026 05:55:51 -0700 Hematopoietic Stem Cell Transplantation in Children With Transfusion Dependent β‐Thalassemia: A Two‐Decade Single‐Center Experience Mon, 12 Oct 2026 05:55:51 -0700 Cognitive Impairment, Depression and Cerebral Microbleeds in Immune Thrombocytopenia (ITP) Mon, 12 Oct 2026 05:55:51 -0700 Real‐World Outcomes of Venetoclax‐Based Therapy in Treatment‐Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study Mon, 12 Oct 2026 05:55:51 -0700 Chronic Anemia Is Associated With Subclinical Myocardial Fibrosis in α‐Τhalassemia Intermedia Mon, 12 Oct 2026 05:55:51 -0700 |
|
|
| |||
|
Thrombophilia testing: does it truly affect risk? October 13 2026 - Volume 10, Issue 19 Beyond hemolysis: redefining pediatric AIHA October 13 2026 - Volume 10, Issue 19 New views on VUSs in RUNX1-FPD October 13 2026 - Volume 10, Issue 19 Democratizing cancer risk testing in children before alloHCT October 13 2026 - Volume 10, Issue 19 CC-486 plus venetoclax: another step toward oral AML therapy October 13 2026 - Volume 10, Issue 19 The roots run deep in therapy-related myeloid neoplasms October 13 2026 - Volume 10, Issue 19 Of mice and FVIIIa mimetics: new hemophilia A models for in vivo evaluation October 13 2026 - Volume 10, Issue 19 CATCHing chronic GVHD October 13 2026 - Volume 10, Issue 19 Canadian emicizumab registry: a blueprint for the future October 13 2026 - Volume 10, Issue 19 HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO) October 13 2026 - Volume 10, Issue 19 CAR-T therapy is the preferred option in relapsed/refractory multiple myeloma October 13 2026 - Volume 10, Issue 19 HMA + venetoclax triplet regimens for the initial treatment of AML in adults October 13 2026 - Volume 10, Issue 19 Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma October 13 2026 - Volume 10, Issue 19 Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin October 13 2026 - Volume 10, Issue 19 Burkitt lymphoma: current understanding, unmet needs, and research directions October 13 2026 - Volume 10, Issue 19 Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis October 13 2026 - Volume 10, Issue 19 MRD negativity by PBMCs and ctDNA confirms deep and durable responses after epcoritamab monotherapy in R/R FL October 13 2026 - Volume 10, Issue 19 Allogeneic HSCT outcomes and impact of defibrotide prophylaxis on SOS after inotuzumab in pediatric B-ALL October 13 2026 - Volume 10, Issue 19 Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis October 13 2026 - Volume 10, Issue 19 Infection burden in mismatched unrelated donor hematopoietic cell transplantation: results from the ACCESS trial October 13 2026 - Volume 10, Issue 19 Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia October 13 2026 - Volume 10, Issue 19 A phase 1b/2 study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMML October 13 2026 - Volume 10, Issue 19 A phase 1/1b study of the all-oral regimen CC-486 and venetoclax in acute myeloid leukemia October 13 2026 - Volume 10, Issue 19 Impact of EBV status and histology on patient outcomes with nivolumab-AVD vs BV-AVD in advanced classic Hodgkin lymphoma (S1826) October 13 2026 - Volume 10, Issue 19 Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML October 13 2026 - Volume 10, Issue 19 Chronic GVHD consortium CATCH study: incidence, initial presentation, and risk factors for chronic GVHD development October 13 2026 - Volume 10, Issue 19 Long-term experience with emicizumab in people with hemophilia A in the Canadian Bleeding Disorders Registry October 13 2026 - Volume 10, Issue 19 Characterization of hematopoietic stem cell–derived microglia-like cells in nonhuman primates October 13 2026 - Volume 10, Issue 19 JARID2 inhibition reprograms human hematopoietic progenitor cells to enhance bone marrow transplantation October 13 2026 - Volume 10, Issue 19 HLH-like syndromes associate with increased risk of death and CD19− relapse after CAR T in pediatric B-ALL October 13 2026 - Volume 10, Issue 19 CD20 bispecific T-cell engager depletes B-cell progenitors preventing EBV-associated lymphomagenesis in humanized mice October 13 2026 - Volume 10, Issue 19 Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia October 13 2026 - Volume 10, Issue 19 Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial October 13 2026 - Volume 10, Issue 19 Genomic architecture of IRF4 rearrangements in childhood and adult large B-cell lymphomas October 13 2026 - Volume 10, Issue 19 Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma October 13 2026 - Volume 10, Issue 19 Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma October 13 2026 - Volume 10, Issue 19 Functional analysis of germline RUNX1 variants identified in individuals with suspected familial platelet disorder October 13 2026 - Volume 10, Issue 19 Comutation of asxl1 and IDH2R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish October 13 2026 - Volume 10, Issue 19 Germ line landscape stratification defines distinct molecular and prognostic groups in therapy-related myeloid neoplasms October 13 2026 - Volume 10, Issue 19 Real-world investigation of germ line predisposition to myelodysplastic syndromes October 13 2026 - Volume 10, Issue 19 Rapid and reproducible karyotyping with long-read sequencing in patients with AML October 13 2026 - Volume 10, Issue 19 A prospective study of familial predisposition to plasma cell dyscrasias October 13 2026 - Volume 10, Issue 19 Predictors of posttransplant measurable residual disease negativity and impact on clinical outcomes in multiple myeloma October 13 2026 - Volume 10, Issue 19 Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations October 13 2026 - Volume 10, Issue 19 Pediatric autoimmune hemolytic anemia is associated with a high incidence of underlying immune disorders October 13 2026 - Volume 10, Issue 19 Characterization of a mouse model to study mechanisms of hemophilia A pain October 13 2026 - Volume 10, Issue 19 Unbiased plasma proteomics reveals hemolysis during ADAMTS13 relapse in patients with immune TTP October 13 2026 - Volume 10, Issue 19 Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase October 13 2026 - Volume 10, Issue 19 A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies October 13 2026 - Volume 10, Issue 19 Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States October 13 2026 - Volume 10, Issue 19 In vivo and ex vivo impact of THBD and PROCR polymorphisms on the anticoagulant response of the protein C pathway October 13 2026 - Volume 10, Issue 19 Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantation October 13 2026 - Volume 10, Issue 19 Chronic graft-versus-host disease after PTCy-based prophylaxis vs non-PTCy prophylaxis October 13 2026 - Volume 10, Issue 19 Frequency, kinetics, and clinical significance of HHV-6 DNAemia after PTCy-based hematopoietic cell transplant October 13 2026 - Volume 10, Issue 19 Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights October 13 2026 - Volume 10, Issue 19 Hydroxyurea reduces hyperadhesion measured by a VLA-4–targeting PET tracer in sickle transgenic Townes mice October 13 2026 - Volume 10, Issue 19 Donor-targeted anti–HLA-A2 antibody shows nanogram-level efficacy in a novel GVHD mouse model October 13 2026 - Volume 10, Issue 19 Are statins interferon’s best friends? Mechanistic insights October 13 2026 - Volume 10, Issue 19 Potential mechanisms of statin and interferon-α2 therapy October 13 2026 - Volume 10, Issue 19 Yu H, Schroeder JA, Mattson JG, Gao C, and Shi Q. Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice. Blood Adv. 2026;10(6):1883-1896. October 13 2026 - Volume 10, Issue 19 |
American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients Blood Adv (2025) 9 (10): 2587–2636. ASH Clinical Practice Guidelines: strategies to stay up-to-date Blood Adv (2023) 7 (21): 6707–6709. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panamena de Hematología, Sociedad Peruana de Hematología, and SVH 2023 guidelines for diagnosis of venous thromboembolism and for its management in special populations in Latin America Blood Adv (2023) 7 (13): 3005–3021. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients Blood Adv (2022) 6 (17): 4975–4982. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients Blood Adv (2022) 6 (17): 4915–4923. American Society of Hematology, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, Sociedad Peruana de Hematología, and SVH 2022 guidelines for prevention of venous thromboembolism in surgical and medical patients and long-distance travelers in Latin America Blood Adv (2022) 6 (12): 3636–3649. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question Blood Adv (2022) 6 (2): 679–685. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis Blood Adv (2022) 6 (2): 664–671. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients Blood Adv (2021) 5 (20): 3951–3959. American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation Blood Adv (2021) 5 (18): 3668–3689. ASH, ABHH, ACHO, Grupo CAHT, Grupo CLAHT, SAH, SBHH, SHU, SOCHIHEM, SOMETH, Sociedad Panameña de Hematología, SPH, and SVH 2021 guidelines for management of venous thromboembolism in Latin America Blood Adv (2021) 5 (15): 3032–3046. Methodology for adaptation of the ASH Guidelines for Management of Venous Thromboembolism for the Latin American context Blood Adv (2021) 5 (15): 3047–3052. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer Blood Adv (2021) 5 (4): 927–974. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19 Blood Adv (2021) 5 (3): 872–888. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease Blood Adv (2021) 5 (1): 301–325. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease Blood Adv (2021) 5 (1): 280–300. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults Blood Adv (2020) 4 (15): 3528–3549. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain Blood Adv (2020) 4 (12): 2656–2701. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences Blood Adv (2020) 4 (10): 2351–2365. |
Ianalumab for the Treatment of Patients with Sjögren’s Disease
21 Oct 2026 Helicobacter pylori Infection — Advances, Challenges, and the Road Ahead 21 Oct 2026 IVUS-Guided PCI in Left Main Coronary Disease 21 Oct 2026 Pulsed Field Ablation for Persistent Atrial Fibrillation 21 Oct 2026 Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer 21 Oct 2026 Mavacamten and Obstructive Hypertrophic Cardiomyopathy in Teens 21 Oct 2026 In Vivo Aquaporin-1 Circular RNA Therapy for Radiation-Induced Xerostomia 21 Oct 2026 Conducting Research with Involuntarily Hospitalized Patients — Ethical, Legal, and Regulatory Considerations 21 Oct 2026 Ianalumab in Sjögren’s Disease — A First Step 21 Oct 2026 Role for Factor XIa Inhibitors after an Acute Coronary Syndrome Event 21 Oct 2026 Infective Endocarditis — When Is Enough Enough? 21 Oct 2026 Tuberculous Empyema Resulting in Pseudochylothorax 21 Oct 2026 Spinal Tuberculosis 17 Oct 2026 Case 30-2026: A 52-Year-Old Man with Vision Loss in the Left Eye 21 Oct 2026 Examining the Use of Race in Clinical Algorithms 21 Oct 2026 What I See before Anyone Speaks 17 Oct 2026 Why Shared-Savings ACOs Have Failed to Deliver for Primary Care 17 Oct 2026 Community Engagement Requirements in Medicaid — Law as a Determinant of Health 17 Oct 2026 Clinical Trial Prediction Markets — Information, at What Cost? 7 Oct 2026 Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes 1 Oct 2026 Continuous Glucose Monitoring in Non–Insulin-Treated Type 2 Diabetes 14 Oct 2026 Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea 21 Oct 2026 Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis 22 Oct 2026 Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis 22 Oct 2026 Intermittent or Continuous Renal-Replacement Therapy in Acute Kidney Injury 14 Oct 2026 Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity 29 Sep 2026 Continuous or Intermittent Renal-Replacement Therapy — What Is the Question? 14 Oct 2026 |
|
|
| |||
|
Highlights of ASCO 2026
Volume 31, Issue 11, November 2026, oyag354 Expression of Concern: Multifocality as a marker of aggressiveness in medullary thyroid carcinoma: a retrospective cohort analysis of lymph node metastasis and recurrence Volume 31, Issue 11, November 2026, oyag383 REVERCE II: a phase II trial of regorafenib followed by anti-EGFR therapy versus reverse sequencing in refractory metastatic colorectal cancer Volume 31, Issue 11, November 2026, oyag307 Comparative safety of concurrent adjuvant trastuzumab emtansine vs trastuzumab with radiotherapy in HER2-positive early breast cancer Volume 31, Issue 11, November 2026, oyag372 Treatment of metastatic solid pseudopapillary neoplasms Volume 31, Issue 11, November 2026, oyag393 Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers Volume 31, Issue 11, November 2026, oyag373 Current landscape of RAS-targeted therapy for pancreatic cancer Volume 31, Issue 11, November 2026, oyag379 Genomic and transcriptomic correlates of deep prostate–specific antigen response in patients with metastatic androgen pathway modulation–sensitive prostate cancer Volume 31, Issue 11, November 2026, oyag368 Long-term outcomes and treatment cessation in patients with response to first-line treatment of metastatic prostate cancer Volume 31, Issue 11, November 2026, oyag375 Toxicity attribution during enfortumab vedotin plus pembrolizumab therapy in urothelial carcinoma: a practical framework Volume 31, Issue 11, November 2026, oyag371 Target trial emulation studies in oncology: a comprehensive analysis Volume 31, Issue 11, November 2026, oyag258 Immune checkpoint inhibitors in resectable and locoregionally advanced HNSCC: past lessons, present evidence, and future directions Volume 31, Issue 11, November 2026, oyag366 Immune checkpoint inhibitors induced autoimmune hemolytic anemia in patients with malignant cancer Volume 31, Issue 11, November 2026, oyag395 Incidence of and risk factors for immune checkpoint inhibitor–related pneumonitis in thoracic malignancies: a prospective multicenter study Volume 31, Issue 11, November 2026, oyag377 Chemotherapy backbone and outcomes of immune checkpoint inhibitor combinations across solid tumors: a pan-tumor network meta-analysis Volume 31, Issue 11, November 2026, oyag365 Aspirational autonomy and psychedelic-assisted therapy in advanced cancer: ethical lessons from clinical cases Volume 31, Issue 11, November 2026, oyag402 Acrokeratosis paraneoplastica (Bazex syndrome): a systematic review and quantitative analysis of 106 cases Volume 31, Issue 11, November 2026, oyag376 Precision oncology at speed: workflow design determines clinical utility in rapid molecular testing for lung cancer Volume 31, Issue 11, November 2026, oyag388 Durable response to vebreltinib in heavily pretreated MET-amplified intrahepatic cholangiocarcinoma: a case report Volume 31, Issue 11, November 2026, oyag409 Between the gate and the stars Volume 31, Issue 11, November 2026, oyag408 Prognostic disclosure, end-of-life communication, and social support associated with distinct dyadic death-preparedness states among cancer dyads Volume 31, Issue 11, November 2026, oyag381 Cannabis assessment in oncology patients—evaluation survey: understanding usage patterns in a rural radiation cohort in Kentucky Volume 31, Issue 11, November 2026, oyag370 Reconsidering the incremental prognostic value of variant allele frequency-based stratification beyond European LeukemiaNet 2022 in acute myeloid leukemia Volume 31, Issue 11, November 2026, oyag406 Correction: Linking early and late endpoints in adjuvant immunotherapy trials: an evaluation of multiple clinical outcomes Volume 31, Issue 11, November 2026, oyag399 |
A Penny for Your Thoughts October 2026: 69(10):2399-2401 Ventral Mesh Rectopexy and Rectal Cancer: An Underrecognized Concern October 2026: 69(10):2402-2403 Artificial Intelligence for Colorectal Surgeons—Part II: Research Applications, Challenges in Adoption, and Practical Resources October 2026: 69(10):2404-2412 What Every Colorectal Surgeon Should Know About Private Equity in Ambulatory Practices: Structure, Practice Models, and Implications for Physicians October 2026: 69(10):2413-2417 Compliance With the American Society of Colon and Rectal Surgeons Preoperative Checklist in Rectal Cancer Care in Ghana: Gaps and Opportunities for Improvement—A Cross-Sectional Study October 2026: 69(10):2418-2424 Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2425-2428 Expert Commentary on Management and Survivorship Considerations in Early-Onset Rectal Cancer October 2026: 69(10):2429-2430 The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Left-Sided Colonic Diverticulitis October 2026: 69(10):2431-2450 Lymph Node Harvest and Prognosis in Stage II and III Rectal Cancer in the Era of Total Neoadjuvant Therapy October 2026: 69(10):2451-2461 Outcomes and Molecular Correlates of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases October 2026: 69(10):2462-2472 Three-Year Follow-up of the Randomized Trial Comparing Open Versus Laparoscopic Surgery for Primary Tumor Resection in Patients With Noncurable Stage IV Colon Cancer (JCOG1107) October 2026: 69(10):2473-2483 Five-Year Follow-up of the Double-Blinded Randomized Controlled Trial Comparing Laser Hemorrhoidoplasty With Sutured Mucopexy and Excisional Hemorrhoidectomy October 2026: 69(10):2484-2491 Patterns and Outcomes of Elective Versus Nonelective Rectal Prolapse Repair: An American College of Surgeons National Quality Surgical Improvement Program Analysis October 2026: 69(10):2492-2499 Short- and Long-term Outcomes of 3-Row Vs 2-Row Circular Staplers for Low Colorectal Anastomosis After Total Mesorectal Excision: A Single-Center, Randomized, Single-Blind, Phase III Trial (THREESTAPLER Study) October 2026: 69(10):2500-2510 Clinical and Physiological Characterization of Neurogenic Bowel Dysfunction in Motor-Incomplete Spinal Cord Injury October 2026: 69(10):2511-2520 Computer Vision Approach to Triaging Patient-Submitted Photos of Intestinal Ostomies October 2026: 69(10):2521-2530 Selected Abstracts October 2026: 69(10):2531-2534 Single Incision Plus One Robot-Assisted Surgery for Right-Sided Colon Cancer October 2026: 69(10):2535-2535 Video Demonstration of Single-Port Robotic Transanal Total Mesorectal Excision Using Newly Developed Surgical Robot System October 2026: 69(10):2536-2537 Mastering the Planes: Laparoscopic Left Hemicolectomy With Complete Mesocolic Excision October 2026: 69(10):2538-2539 |
||
|
| |||
|
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sézary Syndrome
The final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides and Sézary syndrome were recently presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany... Thursday, October 22, 2026 12:45 PM FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors On October 16, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high... Thursday, October 22, 2026 4:30 PM Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials A recent study by researchers from The Univetsity of Texas MD Anderson Cancer Center, ASCO, and collaborating institutions evaluated the national landscape of geographic access to active triple-negative breast cancer clinical trials. The findings—published by Amin et al in Breast Cancer Research... Thursday, October 22, 2026 11:39 AM Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening Among medically underserved adults who smoked and were referred for lung cancer screening, the addition of financial incentives to usual care and free pharmacotherapy significantly increased rates of sustained tobacco abstinence compared with usual care alone or usual care plus free... Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer The addition of metastasis-directed ablation to first-line systemic therapy did not significantly improve progression-free or overall survival in patients with oligometastatic breast cancer, according to findings from the randomized phase II portion of the NRG-BR002 trial reported by Chmura et al... Claudia Henschke, PhD, MD: Finding Lung Cancer in Time I have had many idols in medicine. Many eventually let me down. Remote Expert Case Reviews Identify Opportunities to Improve Cancer Care and Reduce Costs Remote expert review of oncology cases may help to address and improve gaps in evidence-based cancer care, while also providing measurable cost savings, according to findings presented in a poster at the 2026 ASCO Quality Care Symposium (Abstract 700). Wednesday, October 21, 2026 1:00 PM Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction A shorter course of postmastectomy radiation therapy was noninferior to conventional radiation therapy in terms of breast reconstruction complications among women with breast cancer undergoing the procedure, according to findings from the randomized RT CHARM trial reported by Poppe et al in the Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials Clinical trials of adjuvant cancer therapy should do a better job of showing how treatment affects individual patients’ quality of life—particularly when the survival benefit is modest—according to recommendations from Common-Sense Oncology and the European Organisation for Research and Treatment... Starting Surveillance Colonoscopy After High-Risk Adenoma Removal: When Is the Right Time? Surveillance colonoscopy at 5 years after removal of high-risk adenomas was noninferior to surveillance at 3 years in terms of colorectal cancer incidence during the first 5 years after adenoma removal, according to an interim analysis of the randomized EPoS II trial reported by Jover et al in The... AI Model Based on Facial Image Analysis Estimates Biological Age and Mortality Risk in Patients With Cancer Analyzing facial images using a foundational artificial intelligence (AI) model may help researchers determine both biological aging and disease-related mortality risk, according to study findings published in The Lancet Digital Health. Tuesday, October 20, 2026 1:30 PM Community Oncology Practices Bring Advances in Cancer Testing and Treatment Closer to Patients Community oncology practices are bringing personalized medicine into everyday cancer care, substantially expanding their use of advanced biomarker testing and novel therapies for patients with metastatic breast cancer and metastatic non–small cell lung cancer, according to new research from... Tuesday, October 20, 2026 10:55 AM FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA... Friday, October 9, 2026 10:38 AM FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair... Monday, October 19, 2026 3:00 PM National Academy of Medicine Elects 100 New Members for 2026 The National Academy of Medicine (NAM) has announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated... Monday, October 19, 2026 3:06 PM Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera According to findings from the phase III VERIFY trial reported by Kuykendall et al in the Journal of Clinical Oncology, the addition of the hepcidin mimetic rusfertide to standard-of-care therapy significantly improved hematocrit control, reduced the need for phlebotomy, and improved... ASH Issues New Recommendations for the Management of Myelofibrosis The American Society of Hematology (ASH) released new guidelines on the management of myelofibrosis which recommend expanded molecular testing, early transplant referral, appropriate use of JAK inhibitors, and aspirin therapy in select patients. The guidelines were published by Stein et al in Blood ... Monday, October 19, 2026 10:28 AM Immunotherapy-Based Downstaging Linked to Improved Outcomes After Liver Transplantation in Hepatocellular Carcinoma An immune checkpoint inhibitor–based multimodal downstaging strategy before liver transplantation was associated with improved posttransplant survival and a lower risk of recurrence among patients with hepatocellular carcinoma initially beyond the Milan criteria (single lesion not larger than 5 cm... Novel Androgen Receptor Degrader Demonstrates Antitumor Activity in Advanced Prostate Cancer The novel androgen receptor degrader bavdegalutamide demonstrated a manageable safety profile and antitumor activity in patients with metastatic castration–resistant prostate cancer previously treated with androgen receptor pathway inhibitors, particularly those with tumors harboring specific... Verifying the Seen and Unseen by AI in Cancer Imaging Artificial intelligence (AI) can be used in medical imaging and diagnostics to enhance physician capabilities, but also to identify features that humans are not able to see. In research settings, AI has already demonstrated that ability to identify biomarkers from routine medical images and guide... AI-Extracted Chart Data for Expanding Surgical Oncology Learnings Large language models (LLMs) are capable of extracting structured data directly from electronic medical records, expanding data sets available for research, training, and developing artificial intelligence (AI) models. Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families, Study Finds New research published by Rodwin et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that families of children receiving treatment for B-cell acute lymphoblastic leukemia (ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a... Friday, October 16, 2026 11:04 AM Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). Thursday, October 15, 2026 4:39 PM FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). Wednesday, October 14, 2026 12:45 PM Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD... Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer A prospective study found that sentinel lymph node biopsy may be an accurate method of axillary staging in selected patients with locally advanced breast cancer who achieve a clinical nodal response to neoadjuvant chemotherapy—potentially allowing some patients to avoid axillary lymph node... |
Sex-related differences in dynamic right ventricular-pulmonary vascular coupling in heart failure with preserved ejection fraction Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known. Thu, 31 Dec 2020 20:15:06 -0800 Phase II Investigation of the efficacy of Antimycobacterial therapy in Chronic Pulmonary Sarcoidosis A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort. Wed, 30 Dec 2020 20:15:06 -0800 Medical Education During the COVID-19 Pandemic All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators. Tue, 29 Dec 2020 20:15:06 -0800 Impact of Bronchiectasis on incident NTM pulmonary disease: A 10-Year national cohort study Sat, 26 Dec 2020 20:15:06 -0800 Categorized Priority Systems: A New Tool for Fairly Allocating Scarce Medical Resources in the Face of Profound Social Inequities Fri, 25 Dec 2020 20:15:06 -0800 Impact of Right Ventricular Dysfunction on Short- and Long-Term Mortality in Sepsis: A Meta-Analysis of 1,373 Patients In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock. Wed, 23 Dec 2020 20:15:06 -0800 RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study Mon, 21 Dec 2020 20:15:06 -0800 “We usually don’t vote on intubation.” Mon, 21 Dec 2020 20:15:06 -0800 Risk factors, management, and outcomes of legionella pneumonia in a large nationally-representative sample Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP. Sat, 19 Dec 2020 20:15:06 -0800 Which N descriptor is more predictive of prognosis in resected non-small cell lung cancer: the number of involved nodal stations versus the location-based pathological N stage? The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system. Sat, 19 Dec 2020 20:15:06 -0800 Identifying and characterizing a chronic cough cohort through electronic health records NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs. Thu, 17 Dec 2020 20:15:06 -0800 Development and validation of algorithms to identify pulmonary arterial hypertension in administrative data Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source. Thu, 17 Dec 2020 20:15:06 -0800 Development and Prospective Validation of a Deep Learning Algorithm for Predicting Need for Mechanical Ventilation A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care. Thu, 17 Dec 2020 20:15:06 -0800 The clinical use of lung MRI in cystic fibrosis: what, now, how? To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care. Thu, 17 Dec 2020 20:15:06 -0800 Endobronchial Valves for the Treatment of Advanced Emphysema Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success. Thu, 17 Dec 2020 20:15:06 -0800 “How I Do It: Nurse Coordinator Roles and Responsibilities for Bronchoscopic Lung Volume Reduction with Endobronchial Valves” Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC). Tue, 15 Dec 2020 20:15:06 -0800 Oncology Care Provider (OCP) Training in Empathic Communication Skills to Reduce Lung Cancer Stigma Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery. Tue, 15 Dec 2020 20:15:06 -0800 Clinical outcomes and healthcare resource utilization associated with reslizumab treatment in adults with severe eosinophilic asthma in real-world practice In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU. Mon, 14 Dec 2020 20:15:06 -0800 Decreasing case-fatality but not mortality rate following admission to intensive care units in Australia, 2005-2018. Mon, 14 Dec 2020 20:15:06 -0800 Quantitative Emphysema on Low-Dose Computed Tomography of the Chest and Risk of Lung Cancer and Airflow Obstruction: An analysis of the National Lung Screening Trial Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening. Mon, 14 Dec 2020 20:15:06 -0800 |
No cancer research without older adults, from prevention to end of life: a manifesto
Older adults (aged ≥65 years) comprise the majority of people diagnosed with cancer, yet they remain proportionally underrepresented in cancer research at every stage of the pathway. We call on funders, regulators, researchers and journals to make systematic inclusion of older adults the norm, across studies spanning from cancer prevention to end-of-life care. Tue, 20 Oct 2026 00:00:00 -0700 An imprecise label in the era of precision medicine: labelling and access for daraxonrasib, the first pan-RAS inhibitor approval The FDA recently approved daraxonrasib for patients with metastatic pancreatic adenocarcinoma who received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. Critics call the second clause non-evidence based. However, this imprecision enables access: trials generally enrol only patients with good performance status, which does not reflect the realities for most patients with metastatic pancreatic adenocarcinoma who never reach second-line therapy because their clinical condition deteriorates first. Real-world evidence should resolve any remaining uncertainty. Tue, 13 Oct 2026 00:00:00 -0700 A modular framework for antibody–drug conjugate biomarkers Antibody–drug conjugates (ADCs) have transformed the management of various advanced-stage solid cancers. Nonetheless, and despite considerable development efforts, many of these agents lack reliable biomarkers of clinical benefit and/or are reliant on traditional methods of biomarker assessment, with biomarkers of resistance and/or toxicity largely overlooked. In this Review, the authors outline a modular ADC biomarker development strategy that considers the various components of these agents and discuss how biomarkers developed using this strategy might better inform patient selection, therapeutic sequencing, the development of rational combinations, dose optimization and regulatory strategy. Fri, 09 Oct 2026 00:00:00 -0700 Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma Adjuvant radiotherapy improves outcomes in patients with completely resected atypical meningioma Thu, 08 Oct 2026 00:00:00 -0700 Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum The iterative development of several highly effective treatments for HER2-positive breast cancer has transformed patient outcomes, but the now-crowded therapeutic landscape raises questions regarding the optimal approach for each patient. In this Review, the authors outline considerations for right-sizing therapy across the disease continuum, and discuss biomarkers that might facilitate this more individualized approach to treatment. Thu, 08 Oct 2026 00:00:00 -0700 Exercise therapy in cancer prevention and treatment Exercise is widely endorsed as a supportive-care adjunct to mitigate adverse effects of cancer treatment, with data also suggesting potential therapeutic and preventive roles. In this Review, the authors discuss the current evidence from epidemiological studies and clinical trials for exercise as a factor modulating primary cancer risk and disease outcomes after diagnosis, and describe a translational framework for continued development of exercise therapy and a path towards precision exercise oncology. Wed, 07 Oct 2026 00:00:00 -0700 Exploring the immunological effects of antibody–drug conjugates Antibody–drug conjugates (ADCs) have reshaped the therapeutic landscape of many advanced-stage cancers. This clinical activity probably reflects mechanisms beyond targeted cytotoxicity, with emerging evidence suggesting an immune-mediated component. At the same time, regimens combining ADCs with immune checkpoint inhibitors (ICIs) are emerging as a highly effective treatment strategy in various malignancies. In this Review, the authors discuss the immunological mechanisms of action of ADCs, their clinical activity in combination with ICIs, as well as the potential of future agents and regimens to further improve outcomes. Tue, 06 Oct 2026 00:00:00 -0700 Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL Benefit with post-consolidation blinatumomab in newly diagnosed high-risk B-ALL Thu, 01 Oct 2026 00:00:00 -0700 |
|
|
| |||
|
Prognostic significance of DNA damage response-related markers in esophageal squamous cell carcinoma using machine learning approaches
Vol 17, No 4 (August 31, 2026): The association between coffee consumption and esophageal cancer risk: a systematic review and meta-analysis of current observational evidence Vol 17, No 4 (August 31, 2026): FANCI promotes esophageal squamous cell carcinoma progression and cell cycle regulation and interacts with FANCD2 Vol 17, No 4 (August 31, 2026): Human epidermal growth factor receptor 2 expression loss after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma: a retrospective study Vol 17, No 4 (August 31, 2026): Efficacy and safety of sintilimab-based neoadjuvant regimens in patients with resectable gastric or gastroesophageal junction adenocarcinoma: a single-arm systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prediction-model development and temporal validation for six-month cancer-specific mortality in de novo metastatic gastroesophageal junction adenocarcinoma: a SEER-based study Vol 17, No 4 (August 31, 2026): Early hypoalbuminemia during zolbetuximab therapy in gastroesophageal adenocarcinoma: a retrospective observational study Vol 17, No 4 (August 31, 2026): Nodal status and advanced clinical stage as determinants of response and survival after induction chemoradiotherapy in esophageal and gastroesophageal junction cancer: a single-centre retrospective cohort study Vol 17, No 4 (August 31, 2026): Screening of molecular biomarkers ASPN and LBH and construction of a prediction nomogram for the progression of esophagogastric junction adenocarcinoma Vol 17, No 4 (August 31, 2026): Non-structural maintenance of chromosome condensin I complex subunit H knockdown suppresses malignant progression of esophageal squamous cell carcinoma via the Wnt/β-catenin signaling pathway Vol 17, No 4 (August 31, 2026): The prognosis of patients with gastrointestinal stromal tumors harboring the KIT exon 11 mutation: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Cuproplasia-associated LOXL2 cooperates with Helicobacter pylori infection to promote gastric cancer progression via the FAK/Src signaling axis Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram for the non-invasive prediction of human epidermal growth factor receptor 2 expression in gastric adenocarcinoma: an 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based study Vol 17, No 4 (August 31, 2026): Non-invasive prediction of occult peritoneal metastasis (OPM) in gastric cancer using logistic regression and random forest integrative models with CT radiomics and clinical parameters: machine learning prediction of gastric OPM Vol 17, No 4 (August 31, 2026): Helicobacter pylori-induced cystathionine-γ-lyase drives redox imbalance and metabolic remodeling in gastric cancer Vol 17, No 4 (August 31, 2026): Development of a postoperative risk scoring tool for elderly patients with early gastric cancer: an exploratory prognostic score derivation study Vol 17, No 4 (August 31, 2026): Increased expression of Ribonucleic acid export 1 (RAE1) gene promotes gastric carcinogenesis and is associated with Hippo signaling pathway Vol 17, No 4 (August 31, 2026): Impact of spatial distribution of M2 macrophages on prognosis and neoadjuvant chemotherapy resistance in gastric cancer Vol 17, No 4 (August 31, 2026): Distinct metastatic patterns and survival outcomes in intestinal- versus diffuse-type gastric cancer: a SEER-based propensity score-matched analysis Vol 17, No 4 (August 31, 2026): Clinical efficacy and safety of apatinib plus S-1 combined with oxaliplatin (SOX) in postoperative stage III gastric cancer patients with high VEGFR-2 expression Vol 17, No 4 (August 31, 2026): A predictive nomogram model for overall survival in obstructive colorectal cancer based on clinical and laboratory indicators Vol 17, No 4 (August 31, 2026): Trajectory identification of high-risk subgroups after colorectal cancer surgery in patients with minimal residual disease: a single-center longitudinal study Vol 17, No 4 (August 31, 2026): Histopathological subtypes independently predict survival in ampullary carcinoma: a contemporary SEER nomogram study Vol 17, No 4 (August 31, 2026): Sphingosine-1-phosphate induces angiogenesis via the activating STAT3 signaling pathway to drive colorectal cancer progression Vol 17, No 4 (August 31, 2026): Artemisinin inhibits colorectal cancer progression via the FAM83A-AS1/HIF-1α axis Vol 17, No 4 (August 31, 2026): Metabolic-cell-death gene trio predicts survival and cuproptosis sensitivity in colorectal cancer Vol 17, No 4 (August 31, 2026): Real-world efficacy and safety of fruquintinib plus PD-1 inhibitors with or without radiotherapy in refractory metastatic colorectal cancer: a single-center retrospective cohort study Vol 17, No 4 (August 31, 2026): Association between metabolic dysfunction-associated steatotic liver disease and risk of early-onset advanced colorectal neoplasia: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): MS4A3 as a potential prognostic biomarker for colon cancer: integrated analysis of expression patterns and immune cell infiltration Vol 17, No 4 (August 31, 2026): Radiomic prediction of early progression at 2 years post-treatment in patients with resectable rectal cancer based on rectal tumor and mesentery characteristics: a two-center study Vol 17, No 4 (August 31, 2026): Prognostic significance of lymphovascular invasion in colorectal mucinous adenocarcinoma after curative resection: a nationwide multi-center retrospective cohort study Vol 17, No 4 (August 31, 2026): A study on screening of postoperative chemotherapy beneficial populations in stage II colorectal cancer based on diffusion weighted imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography Vol 17, No 4 (August 31, 2026): Prognostic value of genes associated with metastasis and propionate metabolism in rectal cancer Vol 17, No 4 (August 31, 2026): Global, regional, and national burden of colorectal cancer attributable to modifiable risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Vol 17, No 4 (August 31, 2026): Prognostic impact of mucinous adenocarcinoma after curative surgery for stage I–III colorectal cancer: a large population-based cohort study Vol 17, No 4 (August 31, 2026): Comparative analysis of outcomes and sociodemographic factors in early- and late-onset colorectal cancer hospitalizations Vol 17, No 4 (August 31, 2026): Modifiable risk factors contributing to the rising incidence of early-onset colorectal cancer in the United States over three decades: a Global Burden of Disease analysis Vol 17, No 4 (August 31, 2026): Establishment of a chemoradio-resistance colorectal cancer cell model and its changes in biological behavior Vol 17, No 4 (August 31, 2026): Prediction of histological response by PET-CT after 2 weeks of neoadjuvant chemo-radiotherapy for rectal cancer: a prospective clinical trial Vol 17, No 4 (August 31, 2026): Landscape of acquired resistance alterations in gastrointestinal malignancies after genomically targeted therapy Vol 17, No 4 (August 31, 2026): Development and preliminary validation of plasma cell-free DNA methylation-based diagnostic prediction model for colorectal cancer detection Vol 17, No 4 (August 31, 2026): Second-line raltitrexed plus irinotecan (SALIRI) with bevacizumab, cetuximab, or alone for metastatic colorectal cancer: a prospective multicenter cohort-based secondary analysis of the SALLY trial Vol 17, No 4 (August 31, 2026): Application value of dual-phase cone-beam computed tomography during hepatic arteriography in the detection of ≤2 cm hypervascular hepatocellular carcinoma and its feeding arteries Vol 17, No 4 (August 31, 2026): Development and validation of a novel nomogram for predicting long-term survival in gallbladder cancer: a large population-based study using the SEER database Vol 17, No 4 (August 31, 2026): Development and validation of prognostic nomograms for intrahepatic cholangiocarcinoma with concomitant hepatolithiasis after radical resection Vol 17, No 4 (August 31, 2026): Metabolic burden but not metabolic dysfunction-associated steatotic liver disease affects the prognosis of patients with hepatocellular carcinoma after hepatectomy: a retrospective cohort study Vol 17, No 4 (August 31, 2026): Global impact of hepatitis B vaccination on the risk of hepatocellular carcinoma: a systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Immunological characteristics of calmodulin-related genes in hepatocellular carcinoma and their potential for prognostic prediction and diagnostic applications Vol 17, No 4 (August 31, 2026): Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis Vol 17, No 4 (August 31, 2026): Relationships among slow diffusion coefficient and diffusion-derived ‘vessel density’ signal features, Gadoxetate delayed enhancement, tumor size, tumor grading, and patient survival: an exploratory study of mass-forming intrahepatic cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Construction of molecular signatures based on the co-expression network of NECSO-related gene TRPM4 and its prognostic value in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): Organ-specific response to atezolizumab + bevacizumab combination therapy for unresectable hepatocellular carcinoma with extrahepatic metastases: a retrospective cohort study Vol 17, No 4 (August 31, 2026): A practical nomogram for predicting survival in patients with extrahepatic cholangiocarcinoma: a population-based cohort study Vol 17, No 4 (August 31, 2026): SLC25A45 as a prognostic biomarker promotes malignant progression via mutant p53 in hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A novel glutamine metabolism-based classification system for characterizing the heterogeneity of hepatocellular carcinoma Vol 17, No 4 (August 31, 2026): A CFH- and SPINT2-based prognostic signature for cholangiocarcinoma Vol 17, No 4 (August 31, 2026): Evolving burden of pancreatic cancer in the Middle East and North Africa Region, 1990–2023: an analysis based on the Global Burden of Disease Study 2023 Vol 17, No 4 (August 31, 2026): Association between preoperative statin use and survival after pylorus-preserving pancreaticoduodenectomy for pancreatic or periampullary cancer: a propensity score-matched cohort study Vol 17, No 4 (August 31, 2026): Development and validation of a nomogram based on three-dimensional quantitative parameters from dual-layer detector spectral computed tomography for predicting treatment response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma Vol 17, No 4 (August 31, 2026): Chronic psychological stress and gastric cancer: bidirectional associations, biological mechanisms, and clinical implications—a narrative review Vol 17, No 4 (August 31, 2026): MNAT1 in gastrointestinal cancers: mechanistic insights and therapeutic strategies—a narrative review Vol 17, No 4 (August 31, 2026): Impacts of neoadjuvant therapy on subsequent surgical difficulty, safety, and outcomes in locally advanced rectal cancer: a narrative review Vol 17, No 4 (August 31, 2026): From clinical insight to trial design: advancing circulating tumor DNA-informed care in pancreatic cancer Vol 17, No 4 (August 31, 2026): Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial Vol 17, No 4 (August 31, 2026): Neuroendocrine tumors of unknown primary: a case report and review of tumors with gastroenteropancreatic features Vol 17, No 4 (August 31, 2026): Diagnostic biopsy-to-treatment interval and risk of recurrence in localized pancreatic ductal adenocarcinoma: every week counts Vol 17, No 4 (August 31, 2026): Non-operative management of rectal adenocarcinoma in a safety-net system: a decade of real-world outcomes outside watch-and-wait eligibility Vol 17, No 4 (August 31, 2026): Association of ctDNA RAS mutational status and clinical benefits in first-line metastatic colorectal cancer therapy with chemotherapy plus anti-EGFR (overall response rate and progression-free survival): a brief report of systematic review and meta-analysis Vol 17, No 4 (August 31, 2026): Prognostic role of resting heart rate in patients with colorectal cancer Vol 17, No 4 (August 31, 2026): DNA-dependent protein kinase inhibition as a radiosensitizer in rectal cancer: toxicity must be evaluated in the context of organ preservation Vol 17, No 4 (August 31, 2026): Persistent FGFR pathway dependence: where does tinengotinib fit after FGFR inhibitor therapy in advanced cholangiocarcinoma? Vol 17, No 4 (August 31, 2026): Optimizing hepatocellular carcinoma screening in the era of metabolic dysfunction-associated steatotic liver disease and alcohol-related liver disease: time to lower the alpha-fetoprotein threshold Vol 17, No 4 (August 31, 2026): Beyond trastuzumab: redefining first-line HER2-positive gastroesophageal cancer with bispecific HER2 targeting Vol 17, No 4 (August 31, 2026): Identifying actionable targets: predicting imatinib nonadherence in patients with gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Therapeutic drug-monitoring-guided desensitization for severe imatinib-associated rash Vol 17, No 4 (August 31, 2026): Endoscopic ultrasonography ablation for small pancreatic neuroendocrine tumors Vol 17, No 4 (August 31, 2026): Extending the utility of anti-EGFR therapy in metastatic colorectal cancer Vol 17, No 4 (August 31, 2026): Cadonilimab plus chemotherapy in PD-L1-low gastroesophageal cancer: a bispecific opportunity? Vol 17, No 4 (August 31, 2026): Ferroptosis in gastrointestinal stromal tumors Vol 17, No 4 (August 31, 2026): Erratum: Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes Vol 17, No 4 (August 31, 2026): |
|
||
|
| |||
|
Economic Impact of the 2025 New Mexico Measles Outbreak: Highlighting the Cost of Efforts to Prevent Future Outbreaks
Annals of Internal Medicine, Volume 179, Issue 10, Page 1369-1374, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Longitudinal Changes in Heart Stress and the Risk for Cardiovascular Disease and Mortality in Older Adults Annals of Internal Medicine, Volume 179, Issue 10, Page 1375-1385, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Periconception Parental Red Blood Cell Folate, Vitamin B12, and Birth Defects in Offspring Annals of Internal Medicine, Volume 179, Issue 10, Page 1386-1397, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Association Between Blood Hemoglobin Concentration and Mortality by Age and Sex Annals of Internal Medicine, Volume 179, Issue 10, Page 1398-1411, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes Annals of Internal Medicine, Volume 179, Issue 10, Page 1412-1429, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Interventions to Improve Outpatient Follow-up for Hospitalized Patients With Alcohol Use Disorder Annals of Internal Medicine, Volume 179, Issue 10, Page 1430-1443, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Randomized Quality Improvement Trials: An Overview and Proposed Framework for Ethical Oversight Annals of Internal Medicine, Volume 179, Issue 10, Page 1444-1452, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction Annals of Internal Medicine, Volume 179, Issue 10, Page 1460-1472, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 How Would You Screen This 26-Year-Old Woman for Cervical Cancer? Grand Rounds Discussion From Beth Israel Deaconess Medical Center Annals of Internal Medicine, Volume 179, Issue 10, Page 1473-1481, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Ethics and Professionalism in Artificial Intelligence and Medical Practice: A Position Paper From the American College of Physicians Annals of Internal Medicine, Volume 179, Issue 10, Page 1453-1459, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 International Medical Graduates in America: Navigating a Winding History of Immigration Laws and Licensure Requirements Annals of Internal Medicine, Volume 179, Issue 10, Page 1482-1488, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Infection Surveillance at 50: Are We Still Measuring What Matters? Annals of Internal Medicine, Volume 179, Issue 10, Page 1489-1491, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Expediting Access to Biosimilars: Assessing the U.S. Food and Drug Administration’s Revised Approach on Comparative Efficacy Annals of Internal Medicine, Volume 179, Issue 10, Page 1492-1493, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Peer-Unreviewed: When the Thread Replaces the Paper Annals of Internal Medicine, Volume 179, Issue 10, Page 1494-1495, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Health Inequities Training Threatened by Revised Liaison Committee on Medical Education Standards Annals of Internal Medicine, Volume 179, Issue 10, Page 1496-1497, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Artificial Intelligence and the Risk of Self-fulfilling Prophecies Annals of Internal Medicine, Volume 179, Issue 10, Page 1498-1499, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 N-Terminal Pro–B-Type Natriuretic Peptide in Older Adults: Biomarker and Barometer of Biological Aging Annals of Internal Medicine, Volume 179, Issue 10, Page 1500-1501, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Both Paternal and Maternal Nutrition Status Matter: An Exemplar From Folate and Vitamin B12 in Association With Risks for Birth Defects Annals of Internal Medicine, Volume 179, Issue 10, Page 1502-1503, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Ethical Oversight of Randomized Quality Improvement Trials: A Pragmatic Approach Annals of Internal Medicine, Volume 179, Issue 10, Page 1504-1505, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Super Mario Soldiers Annals of Internal Medicine, Volume 179, Issue 10, Page 1506-1507, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 “When I Was a Resident …” Annals of Internal Medicine, Volume 179, Issue 10, Page 1508, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 The Doctor in the Waiting Room Annals of Internal Medicine, Volume 179, Issue 10, Page 1509-1510, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Still, We Return Annals of Internal Medicine, Volume 179, Issue 10, Page 1511-1512, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Benzodiazepine Prescriptions to Older Adults in the United States, 2015 to 2024 Annals of Internal Medicine, Volume 179, Issue 10, Page 1514-1519, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Provision of Onsite Prenatal Care Services at U.S. Federally Qualified Health Centers Annals of Internal Medicine, Volume 179, Issue 10, Page 1519-1522, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 Quality Indicators for Diabetes in Adults Annals of Internal Medicine, Volume 179, Issue 10, Page 1524, October 2026. <br/> Tue, 04 Aug 2026 07:00:00 +0000 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 SITC 2025: Macrophage-targeting CAR monocytes Improve Immunotherapy Outcomes in Breast Cancer SITC 2025: Results from the Phase 1 / 2a AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumors SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors SITC 2025: Long-term Complete Responses of T-Cell Therapies for HPV-Related Cancers ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: Higher Thymic Health Linked to Better Patients’ Response to Immunotherapy October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Zongertinib Shows a 77% ORR in Treatment-naïve Patients with Advanced HER2 Mutant NSCLC October 18, 2025 ESMO 2025: First Phase 1 Safety and Efficacy Data Presented of Izalontamab Brengitecan in Patients with Advanced Solid Tumors October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide
November 20, 2025 Pediatric Oncology: Novel Treatment Proves ‘Miracle’ for 6-Year-Old with Leukemia Jiahui International Cancer Center Successfully Treats a 78-year-old Patient from New Zealand with Advanced CAR T-Cell Therapy SITC 2025: Data Shows Promising Preclinical Results for SynKIR™-110 in Solid Tumors Combination Treatment of Ianalumab + Ibrutinib May Help Some Patients to Discontinue Daily Therapy Liposomal Spherical Nucleic Acids Constructs Impact both Chemotherapeutic Delivery and Cell Targeting November 1, 2025 Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma Shows Positive Topline Results October 24, 2025 Study Identifies TRβ as a Targetable Driver in the Growth of Prostate Cancer October 21, 2025 ESMO 2025: A ctDNA-guided Approach to Helps Personalize Adjuvant Chemotherapy Colon Cancer October 20, 2025 ESMO 2025: Circulating Tumor DNA (ctDNA)–guided Treatment in Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer October 20, 2025 ESMO 2025: Vimseltinib Demonstrates Statistically Significant and Clinically Meaningful Benefit in Patients Diagnosed with Tenosynovial Giant Cell Tumor October 20, 2025 ESMO 2025: Belzutifan Shrinks Rare Neuroendocrine Tumors and Improves Patients Symptoms October 20, 2025 ESMO 2025: Previously Treated Advanced Kidney Cancer Patients may Benefit from Targeted Therapies October 19, 2025 ESMO 2025: A New Generation of Antibody-drug Conjugates Demonstrates Unprecedented Promise in Early-Stage Breast Cancer October 19, 2025 ESMO 2025: First In Human Dose Escalation for TT125-802 Shows Durable Confirmed Responses in Non-small Cell Lung Cancer October 18, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 FDA’s Plan To Boost Biosimilar Drugs Could Stall at the Patent Office November 17, 2025 Agency, Adaptation, and Access: Hospitals Leveraging Locum Tenens to Bridge the Physician Gap November 14, 2025 ESMO 2025: Further Phase 3 COMPETE Trial Analysis Demonstrates Clinical Efficacy and Safety of Radiopharmaceutical n.c.a. ¹⁷⁷Lu-edotreotide November 20, 2025 Study Shows Intranasal Vaccine Offers Promise as a Non-invasive Therapeutic Option for Treatment of Cervical Cancer November 19, 2025 Cancer Cells Use the ‘Adaptive Processes’ to Initiate Resistance and Survive Treatment November 19, 2025 Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics December 19, 2018 How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall? October 9, 2018 Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’ Against Cancer November 30, 2013 |
|
|
| |||
|
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3 A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipolar mania.
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio.
As AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision AbbVie’s next-gen dual-targeting therapy elicited higher rates of remission than its IL-23 inhibitor Skyrizi in a Phase 2a trial of Crohn’s disease, leading analysts to wonder if the blockbuster can be outdone.
Novartis ends mid-stage Fabhalta study in lupus, insists no efficacy or safety issues Novartis will continue to study Fabhalta in other indications, with late-stage studies in two rare diseases—atypical haemolytic uraemic syndrome and generalized myasthenia gravis—expected to read out later this year and next year, respectively.
Arrowhead’s blood-brain barrier tech is ‘arguably better’ than others, analysts say after data drop Arrowhead Pharmaceuticals’ siRNA candidate achieved “compelling” tau reductions in an early study of healthy volunteers, with a magnitude of effect that seems to outperformother blood-brain barrier platforms, according to Stifel.
Verastem reports ‘robust’ response rate in pancreatic cancer subgroup where Rasonque struggled Revolution Medicines’ recently approved drug showed a 24% overall response rate and a high rate of side effects in patients whose cancer has a G12D mutation, reinforcing Mizuho’s view that a more specific agent such as Verastem Oncology’s VS-7375 “should come first for G12D patients.”
Syndax ends fibrosis program for Niktimvo after mid-stage disappointment Syndax Pharmaceuticals will no longer test Niktimvo for idiopathic pulmonary fibrosis, but the company’s work to expand the drug’s label in chronic graft-versus-host disease, for which it was approved in 2024, will continue.
Salubris Biotherapeutics Announces Updated Phase 1b/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology Congress 2026 Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 Marengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer Marengo Therapeutics Announces Landmark Nature Medicine Publication Establishing First-in-Human Proof of Vβ-Directed T-Cell Biology and Antitumor Activity Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy Enterome Phase 1/2 data show OncoMimics™ EO4010-induced CD8 T-cell expansion was associated with longer survival in patients with colorectal cancer Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026 Vicore’s Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results Walden Biosciences Announces Positive Data from Diabetic Kidney Disease Cohorts in Ongoing Phase 2 Study of WAL0921 DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Rgenta Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Trial Design for RGT-61159 in Patients with Adenoid Cystic Carcinoma (ACC) Acumen Pharmaceuticals to Present Preliminary Baseline Characteristics and Data on Care Experiences and Participation in Phase 2 ALTITUDE-AD Trial at the 19th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference Bio-Thera to Present Phase 2 Clinical Data for BAT8008 in Combination with BAT1308 at ESMO 2026 BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer Sundance Biosciences Announces First Patient Dosed in U.S. Phase 2 Clinical Trial of SUN-627 for Progressive Forms of Multiple Sclerosis (MS) Apollo Therapeutics Announces Science Translational Medicine Publication Supporting APL-9796 as a Potential Disease-Modifying Approach for Pulmonary Hypertension Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment |
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.
Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infectious uveitis trials, leading analysts to say the candidate “looked superior to Humira.”
Epkinly data only one of Genmab’s make-or-break readouts ahead of steep sales erosion Bracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.
Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweep Disc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria were able to spend in the sun and artificial light.
Veradermics’ minoxidil pill improves hair coverage in men in Phase 3 In the wake of a successful IPO and strong stock growth throughout the year, Veradermics now has late-stage data to support a regulatory package for its hair loss pill.
Vanda freezes Novartis-originated social anxiety program after late-stage disappointment While Oppenheimer doesn’t see the Phase 3 stumble of VQW-765 as highly detrimental to Vanda Pharmaceuticals, the analyst nevertheless believes the stakes are now higher for the company’s planned Q4 readout for Nereus in GLP-1-induced vomiting.
BMS’ Phase 3 win for lung drug clouded by high-dose miss A low-dose win could derisk a regulatory pathway for BMS’ LPA1 antagonist in idiopathic pulmonary fibrosis after a recently reported patient death, but a miss at the higher dose leaves analysts awaiting full data.
RevMed’s Rasonque gets a subtype data asterisk, but analysts remain bullish Data released by the FDA show that Revolution Medicine’s newly approved pancreatic cancer drug underperformed in a large subgroup of patients, but analysts say the biotech still has a clear winner.
BMS’ $4.1B RayzeBio bet delivers Phase 3 radiopharma win The centerpiece of Bristol Myers Squibb’s 2024 RayzeBio buy has read out, hitting the primary endpoint in a late-stage tumor trial.
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial HUYABIO International Announces HBI-8000 and Nivolumab Combination Reduces the Risk of Disease Progression by 27% in Patients with Advanced Melanoma in Phase 3 Trial Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA® (pembrolizumab) at ESMO 2026 Presidential Symposium Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026 Otsuka Presents Landmark Final Phase 3 VISIONARY Results at ASN Demonstrating VOYXACT® (sibeprenlimab-szsi) Stabilized Kidney Function and Reduced Risk of Disease Progression and Kidney Failure, Redefining Treatment Paradigm in IgA Nephropathy DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa Granata Bio Completes Screening in Phase III GRACE Study of GB-hMG Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa Rgenta Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Trial Design for RGT-61159 in Patients with Adenoid Cystic Carcinoma (ACC) Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne |
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial
The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.
ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3 A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late-stage trial, but the results have disappointed some analysts, raising questions about its commercial prospects.
GSK, Ionis hepatitis B functional cure breaks open market for followers The approval of Hibsago has created a new market for a handful of biopharmas, including Gilead, Arrowhead, and Vir, to fill in.
Why investors are taking another look at kidney disease In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.
Roivant’s TYK2/JAK inhibitor reduces need for steroids in inflammatory eye disease Brepocitinib is on a roll. After winning approval for an autoimmune skin disease, Roivant Sciences subsidiary Priovant’s drug hit all primary and secondary endpoints in a pair of Phase 3 non-infectious uveitis trials, leading analysts to say the candidate “looked superior to Humira.”
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck, and Summit Therapeutics.
Rapport ekes out bipolar mania win as lead asset ‘just hits’ in mid-stage trial Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential pipeline-in-a-product—this time showing improvement in symptoms of bipolar mania.
Gilead’s ‘highly competitive’ mid-stage ulcerative colitis data ‘validate’ I&I push Gilead’s emvistegrast delivered greater clinical response than placebo, setting up the asset for Phase 3 testing in ulcerative colitis as well as studies in other inflammatory diseases and bolstering the company’s push beyond its HIV portfolio.
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 Salubris Biotherapeutics Announces Updated Phase 1b/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology Congress 2026 Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2- Breast Cancer in Phase 3 PANKU-Breast01 Study Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment Marengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade TORL BioTherapeutics Presents Preliminary Safety and Efficacy Data of Ixotatug Vedotin Monotherapy in Treatment-Refractory Germ Cell Tumors at the ESMO Congress 2026 Kisqali® shows clinically meaningful overall survival in broadest HR+/HER2- early breast cancer population at high risk of recurrence BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026 Marengo Therapeutics Announces Landmark Nature Medicine Publication Establishing First-in-Human Proof of Vβ-Directed T-Cell Biology and Antitumor Activity Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas 2026 ESMO LBA | Innovent Announces International Phase 3 Study of Arcotatug Tavatecan (CLDN18.2-ADC) in Gastric Cancer Met Dual Primary Endpoints of PFS and OS AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial |
|
|
| |||
|
FDA grants traditional approval for pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph for unresectable or metastatic TMB-H solid tumors with updated indication
On October 16, 2026, the Food and Drug Administration granted traditional approval to pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) for adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥13 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Thu, 22 Oct 2026 00:00:01 -0700
FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer On October 19, 2026, the Food and Drug Administration granted accelerated approval to dostarlimab (Jemperli, GSK) for adults with Stage II/III locally advanced rectal cancer (LARC) that is microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR), as determined by an FDA-authorized test for solid tumors.
Mon, 19 Oct 2026 00:00:01 -0700
FDA approves an expanded indication for nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer On October 14, 2026, the Food and Drug Administration (FDA) approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.) with Bacillus Calmette-Guérin (BCG) for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This revises the prior indication for adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) with or without papillary tumors to include patients with high-grade papillary-only tumors.
Wed, 14 Oct 2026 00:00:01 -0700
FDA approves atezolizumab in combination with chemotherapy for Stage III mismatch repair deficient colon cancer On October 8, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients two years of age and older with Stage III mismatch repair deficient (dMMR) colon cancer. The FDA also approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients 12 years of age and older who weigh 40 kg or greater with Stage III dMMR colon cancer.
Thu, 08 Oct 2026 00:00:01 -0700
FDA approves tucatinib with trastuzumab and pertuzumab for the maintenance treatment of HER2-positive breast cancer On October 7, 2026, the Food and Drug Administration approved tucatinib (Tukysa, Seagen Inc., a subsidiary of Pfizer) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment.
Wed, 07 Oct 2026 00:00:01 -0700
FDA approves pirtobrutinib for previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma On October 2, 2026, the Food and Drug Administration approved pirtobrutinib (Jaypirca, Eli Lilly and Company) for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.
Fri, 02 Oct 2026 00:00:01 -0700
FDA approves belzutifan in combination with lenvatinib for advanced renal cell carcinoma with a clear cell component On September 24, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with lenvatinib (Lenvima, Eisai Inc.) for adults with advanced renal cell carcinoma with a clear cell component (ccRCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.
Thu, 24 Sep 2026 00:00:01 -0700
FDA approves lirafugratinib for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma On September 23, 2026, the Food and Drug Administration approved lirafugratinib (Lyrfigtu, Elevar Therapeutics, Inc.), a kinase inhibitor, for the treatment of adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 (FGFR2) gene fusion or other rearrangement.
Wed, 23 Sep 2026 00:00:01 -0700
FDA approves imlunestrant in combination with abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. Inluriyo and Verzenio are manufactured by Eli Lilly and Company.
Fri, 18 Sep 2026 00:00:01 -0700
FDA grants accelerated approval to sevabertinib for locally advanced or metastatic non-squamous non-small cell lung cancer On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Wed, 09 Sep 2026 00:00:01 -0700
FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
Fri, 04 Sep 2026 00:00:01 -0700
FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
Wed, 26 Aug 2026 00:00:01 -0700
FDA approves zanidatamab-hrii and tislelizumab-jsgr for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma Tue, 25 Aug 2026 00:00:01 -0700
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
Thu, 13 Aug 2026 00:00:01 -0700
FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Thu, 06 Aug 2026 00:00:01 -0700
FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
Fri, 31 Jul 2026 00:00:01 -0700
FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
Wed, 22 Jul 2026 00:00:01 -0700
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
Tue, 14 Jul 2026 00:00:01 -0700
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
Tue, 14 Jul 2026 00:00:01 -0700
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC). This extends the prior approval for the regimen in this setting from patients who are cisplatin-ineligible to all patients with MIBC who are candidates for cystectomy.
Fri, 10 Jul 2026 00:00:01 -0700
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications On July 9, 2026, the Food and Drug Administration approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications.
Thu, 09 Jul 2026 00:00:01 -0700
FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.
Tue, 30 Jun 2026 00:00:01 -0700
FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC).
Wed, 24 Jun 2026 00:00:01 -0700
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
Wed, 24 Jun 2026 00:00:01 -0700
|
Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
Neurology. 2020 Oct 20;95(16):e2295-e2304. doi: 10.1212/WNL.0000000000010643. Epub 2020 Sep 2. Weigand AJ, Bondi MW, Thomas KR, Campbell NL, Galasko DR, Salmon DP, Sewell D, Brewer JB, Feldman HH, Delano-Wood L; Alzheimer's Disease Neuroimaging Initiative Toxicological alert: Exposure to glycidyl methacrylate and cancer risk. Toxicol Ind Health. 2020 Dec;36(12):937-939. doi: 10.1177/0748233720957816. Epub 2020 Nov 6. Fernandes BJD, Couto RD A general scaling law reveals why the largest animals are not the fastest. Nat Ecol Evol. 2017 Aug;1(8):1116-1122. doi: 10.1038/s41559-017-0241-4. Epub 2017 Jul 17. Hirt MR, Jetz W, Rall BC, Brose U Self-medication of attention-deficit/hyperactivity disorder symptoms with psychoactive substances in adults: a scoping review of how symptom-relief motives are framed and operationalised across substances. Front Psychiatry. 2026 Sep 30;17:1966206. doi: 10.3389/fpsyt.2026.1966206. eCollection 2026. Adamou M, Petrou C Prenatal Sonographic Features of Ring Chromosome 15: A Case Report and Literature Review. Diagnostics (Basel). 2022 Apr 1;12(4):885. doi: 10.3390/diagnostics12040885. Traisrisilp K, Yanase Y, Phirom K, Tongsong T Whole-blood transcriptomic findings in emergency department patients with suspected cannabinoid hyperemesis syndrome: a pilot study. J Cannabis Res. 2026 Jul 23;8(1):110. doi: 10.1186/s42238-026-00477-x. Meltzer A, Cooper ZD, Heidish R, Loganathan A, Loganathan T, Bolden T, Lagunazad I, Perkins J, Jaatinen K, Adelman J, Miller J, Eucker SA, Phillips E, McCaffrey TA Updated treatment targets in inflammatory bowel disease (STRIDE-III): an initiative of the International Organization for the Study of IBD. Lancet Gastroenterol Hepatol. 2026 Oct 19:S2468-1253(26)00292-X. doi: 10.1016/S2468-1253(26)00292-X. Turner D, Ricciuto A, Yuval Bar-Asher S, Vuyyuru SK, Solitano V, Bock N, Estevinho MM, Yuan Y, Iacucci M, Rieder F, Leong RW, Reinisch W, Loftus EV Jr, Peyrin-Biroulet L, Danese S, Panaccione R, Yamamoto T, Schreiber S, Dubinsky M, Ahuja V, Bernstein CN, Rubin DT, Mantzaris GJ, Magro F, Dotan I, Jairath V, Dignass A Photobiomodulation as a Potential Adjunct to Improve the Predictability of Mandibular Incisor Autotransplantation to the Maxillary Lateral Incisor Site in Orthodontic Patients. Photodiagnosis Photodyn Ther. 2026 Oct 20:105694. doi: 10.1016/j.pdpdt.2026.105694. Bahrami R Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord. 2019 May;30:51-56. doi: 10.1016/j.msard.2019.01.048. Epub 2019 Feb 2. Kaisey M, Solomon AJ, Luu M, Giesser BS, Sicotte NL Chronic inhalation toxicity of size-separated glass fibers in Fischer 344 rats. Fundam Appl Toxicol. 1993 May;20(4):464-76. doi: 10.1006/faat.1993.1057. Hesterberg TW, Miiller WC, McConnell EE, Chevalier J, Hadley JG, Bernstein DM, Thevenaz P, Anderson R [An unexpected cause of face presentation: iniencephaly]. Pan Afr Med J. 2016 Nov 24;25:188. doi: 10.11604/pamj.2016.25.188.10900. eCollection 2016. Ayachi A, Mourali M Brain Tumor Stem Cells Remain in Play. J Clin Oncol. 2017 Jul 20;35(21):2428-2431. doi: 10.1200/JCO.2017.73.9540. Epub 2017 Jun 22. Parada LF, Dirks PB, Wechsler-Reya RJ Unilateral amelia with limb deformities and multiple congenital malformations in a newborn: a case report from Palestine. Ann Med Surg (Lond). 2025 Feb 11;87(2):1052-1056. doi: 10.1097/MS9.0000000000002913. eCollection 2025 Feb. Oweidat M, Alra'e M, Aldwaik M, Shubietah A Human coinfection with Bartonella henselae and two hemotropic mycoplasma variants resembling Mycoplasma ovis. J Clin Microbiol. 2010 Oct;48(10):3782-5. doi: 10.1128/JCM.01029-10. Epub 2010 Aug 11. Sykes JE, Lindsay LL, Maggi RG, Breitschwerdt EB Lifetime Cannabis Use Is Associated With Brain Volume and Cognitive Function in Middle-Aged and Older Adults. J Stud Alcohol Drugs. 2026 Jul;87(4):739-751. doi: 10.15288/jsad.25-00346. Epub 2025 Dec 11. Guha A, Fu Z, Calhoun V, Hutchison KE Triploidy and Routine Combined First Trimester Pregnancy Screening. Avicenna J Med Biotechnol. 2019 Jan-Mar;11(1):124-126. Eftekhariyazdi M, Khaligh A, Suizi B, Naghibi Nasab M, Zare-Abdollahi D A microbiome-bile acid axis mediates protection from chronic liver disease in females. Cell. 2026 Oct 19:S0092-8674(26)01194-3. doi: 10.1016/j.cell.2026.09.048. Li M, Kuang J, Chen T, Ding K, Chen Y, Jiao F, Li Y, Luo P, Xia L, Zhang H, Wang J, Zheng D, Zhao M, Sun T, Chao X, Guo Y, Zhu M, Sun Y, Xia X, Ge K, Qu C, Yao C, Xie G, Zhou K, Louca P, Menni C, Zhao A, Guo Q, Wan X, Zhang L, Ji G, Zhou J, Hu C, Jia W, Zheng X, Jia W A rare case of craniofacial morphology with absent face and neck structures, with its review. J Clin Diagn Res. 2013 May;7(5):924-6. doi: 10.7860/JCDR/2013/5516.2978. Epub 2013 May 1. Prasanna LC, Bhat KM, D'Souza AS Cyclic GMP causes Ca2+ desensitization in vascular smooth muscle by activating the myosin light chain phosphatase. J Biol Chem. 1997 Feb 21;272(8):5063-8. doi: 10.1074/jbc.272.8.5063. Lee MR, Li L, Kitazawa T Recruit and retain a diverse workforce. Nat Rev Chem. 2020 Sep;4(9):435-437. doi: 10.1038/s41570-020-0214-z. Manuel BA, Karloff DB |
||